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Electrogenetherapy of Established B16 Murine Melanoma by  
Using an Expression Plasmid for HIV-1 Viral Protein R 
 
Andrea Nicole McCray  
 
Abstract 
 
Novel therapies and delivery methods directed against malignancies such as 
melanoma, and particularly metastatic melanoma, are needed. The HIV-1 accessory 
protein Vpr (viral protein R) has previously been demonstrated to induce G2 cell 
cycle arrest as well as in vitro growth inhibition/killing of numerous tumor cell lines. 
In vivo electroporation has been utilized as an effective delivery method for 
pharmacologic agents as well as DNA plasmids that express “therapeutic” proteins 
and has been targeted to various tissues including malignant tumors. In this study, we 
assessed the ability of electroporation-mediated delivery of Vpr plasmid (pVpr) to 
induce growth attenuation or complete tumor regression in C57BL/6 mice with 
subcutaneous B16.F10 melanoma lesions. To assess the administration of 
intratumoral delivery of pVpr with in vivo electroporation, a range of Vpr plasmid 
dosages, electroporation parameters, and treatment days were evaluated in a 
subcutaneous B16 murine melanoma model. pVpr was injected directly into the 
tumors. Immediately following the injection, the subcutaneous tumors were 
electroporated. Treatment with 25 µg or 100 µg of pVpr plus electroporation on days 
0 and 4 resulted in complete tumor regressions with long-term survival in 14.3% and 
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7.1% of the mice, respectively. In order to optimize the treatment regimen, B16 
tumors were treated on days 0, 2, and 4 with 100 μg pVpr plus electroporation which 
resulted in 50% of the mice with complete tumor regressions and long-term survival. 
Additional investigations revealed intratumoral Vpr expression and demonstrated that 
apoptosis was the mechanism by which Vpr caused tumor regression in vivo. This 
study confirmed that treatment with 100 μg of pVpr plus electroporation led to 
durable complete regressions in established murine melanoma lesions. The pVpr plus 
electroporation treatment regimen has induced complete regressions in mice as well 
as resistance to tumor challenge in some of the animals. This is the first 
comprehensive study demonstrating the ability of Vpr, when delivered as a DNA 
expression plasmid with in vivo electroporation, to induce complete tumor regressions 
coupled with long- term survival of mice in a highly aggressive and metastatic solid 
tumor model.
 
 
 
 
 
Introduction 
 
Cutaneous Melanoma 
Melanoma accounts for only 4% of skin cancers but is responsible for nearly 80% 
of the mortality from these cancers, due to metastatic spread (1). Human melanoma 
develops from malignant melanocytes that travel to the epidermis (2). Differentiated 
melanocytes are located in the basal layer of the epithelium where they produce melanin 
(3). A majority of melanomas that are diagnosed are categorized as either melanoma in 
situ or superficial spreading melanoma because the lesion originates as a radial growth 
phase (2-4). However, some melanomas undergo a vertical growth phase. Nodular 
melanoma is the second most common form of melanoma and demonstrates vertical 
growth (3-5). A primary melanoma which demonstrates both a tumor thickness greater 
than 2 mm and vertical growth has a greater metastatic potential if left untreated than an 
in situ melanoma growing in radial phase. Features of metastatic melanoma include 
melanin in some portion of the tumor, a nest of malignant cells clumped in one region, 
epithelioid and spindle cells (3). 
In 2002, the American Joint Committee on Cancer (AJCC) revised the staging 
system of melanoma, primary tumor, node, metastasis classification (6,7). According to 
the AJCC, stages I and II pertain to primary tumors in which disease has not spread to the 
lymph node. Stage III pertains to local lymph node participation and “in transit” 
metastases (8). Stage IV involves systemic metastases.  
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Many prognostic factors for cutaneous melanoma have been examined throughout 
the years. The most critical prognostic factors include primary tumor thickness, 
ulceration of tumor, number of lymph nodes involved in metastasis, sentinel lymph node 
detection of micrometastasis, and regions of distant metastasis (6,7). Certain prognostic 
factors are more crucial in predicting survival rates in comparison to other prognostic 
factors depending on the stage of disease.  
The main prognostic factors that influence survival rates for stage I and II patients 
are tumor thickness and ulceration. In stage I disease, surgery can be postponed for more 
than three weeks after biopsy without the patient’s five year outcome being adversely 
affected (9). Immense tumor thickness is indicative of lower survival rates (10,11).The 
more ulcerative a tumor appears, the lower the survival rate (12,13) 
Stage III melanoma involves metastasis. Metastasis in the lymph nodes may be 
detected at various time points during disease: when primary melanoma is detected; after 
treatment of the primary melanoma; or develop without an identified primary melanoma. 
No matter which method/route was used for lymph node metastasis to form, survival 
rates are not delineated until after the metastasis is discovered (8). The greater the 
number of local lymph nodes with metastasis, the lower the survival rate of patients after 
10 years (12,14). The Sydney Melanoma Unit/University of Alabama at Birmingham 
(SMU/UAB) study demonstrated that Stage III patients with one positive lymph node had 
40% survival, whereas patients with greater than 5 positive lymph nodes had only 15% 
survival at 10 years (12). Even in Stage III disease, tumor ulceration is a serious problem 
in terms of percent survival rates. The important prognostic factors for stage III: number 
 3
of lymph nodes involved in metastasis, an ulcerated primary melanoma, and nodal size 
(6,7,12). Systemic interferon therapy enhances the survival rate of stage III patients.  
Stage IV patients have more of a problem than the patients in other stages of 
disease. Sites of stage IV metastasis include the skin, soft tissue, or remote lymph nodes 
for the first sites. A secondary site of metastasis is the lungs. Brain, liver, and bone cancer 
can also arise from metastatic melanoma (8). In stage IV, the focus is no longer on the 
primary tumor as an indication for survival rates. The main prognostic factor is the 
anatomic location of the metastasis (6,7). 
Melanoma Markers Detected in Patients 
There are a variety of tumor associated markers linked to melanoma. One of these 
markers, tyrosinase, is an enzyme involved in the synthesis of melanin. Since tyrosinase 
is expressed on normal and malignant melanocytes, it is categorized as an expressed, 
nonmutated differentiation antigen similar to MART-1 and gp100. MART-1 is defined as 
Melanoma Antigen Recognized by T cells. MAGE-3 is a Melanoma Antigen Gene which 
has antigens expressed on only cancer cells and the testis. MUC-18 and p97 are 
melanoma-associated antigens. 
Tyrosinase, MAGE-3, Muc-18, and p97 were found in individuals with melanoma 
by using a multiple-marker assay. The multiple-marker assay involves using RT-PCR to 
test peripheral-blood lymphocytes (PBL) for the simultaneous presence of tyrosinase, 
MAGE-3, MUC-18, and p97. The multiple-marker assay was first optimized in vitro by 
using melanoma cell lines and PBL derived from normal volunteers to examine the 
presence of tyrosinase, MAGE-3, MUC-18, and p97. The results demonstrated that all 
four melanoma markers were present in at least 80% of the melanoma cell lines and only 
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2 of the normal volunteers had MUC-18(15). By using the same multiple-marker assay 
system on PBLs taken from melanoma patients, it was demonstrated that tyrosinase, 
MAGE-3, MUC-18, and p97 markers were detected in the melanoma patients. As the 
clinical stage of disease evolved from stage I to stage IV, there was a significant 
correlation between the number of the aforementioned tumor markers and the stage of 
disease. Therefore, stages II, III, and IV melanomas had the most tumor markers. Also, 
proteins such as MART-1/Melan-A and gp100 have been detected in lesions from 
metastatic patients (16). 
 
Diagnosis of Melanoma 
Biopsy and Dermoscopy 
Biopsy is a technique used to obtain samples for pathologic diagnosis. Biopsy is 
the main method by which suspicious lesions may be diagnosed as melanoma or 
nonmelanoma (17). One type of biopsy is an incisional biopsy. An incisional biopsy is 
performed by using a scalpel or biopsy punch to extract only a section of the tumor. 
During an incisional biopsy, there is removal of the most raised section of the tumor, or 
the darkest region if the tumor is flat (17).  
A noninvasive procedure used to identify possible melanomas is dermoscopy. 
Dermoscopy involves transillumination of the suspected region. Immersion oil is placed 
onto the pigmented region and inspected by a dermoscope, which is a lens that has a 
transilluminating light source. This procedure enables the physician to visualize 
structures underneath the skin surface. 
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Issues Concerning the Eradication of a Solid Tumor and  
Prevention of Tumor Recurrence 
Cancer treatment modalities such as immunotherapy must contend with the issue 
of cancer cells evading the immune system, thereby avoiding destruction. In one 
scenario, the immune system may not mount an immune response to tumor cells, even 
though antigen presenting cells (APCs) may have the capacity to present tumor antigens 
but be incapable of reaching T cell regions of the lymph nodes and fail to activate T cells 
(18). Another mechanism of tumor evasion is the downregulation of certain molecules 
such as MHC molecules or principal tumor antigens. Some tumor cells have developed a 
resistance to apoptosis by overexpression of anti-apoptotic proteins or downregulation of 
pro-apoptotic proteins (18).  
The process of a melanocyte converting into melanoma may be accompanied by 
the loss of HLA class I and HLA class II antigens (8). Twenty-one percent of primary 
human melanoma cells are deficient in HLA-A2 and/or A28. However, forty-four percent 
of human metastatic melanoma cells are deficient in HLA-A2 and/or A28 (19).  
There are various categories of human melanoma antigens that are recognized by 
T cells. The main divisions of melanoma antigens include antigens mainly expressed by 
tumor cells; melanocyte differentiation antigens; antigens that are largely expressed on 
tumors; and melanoma specific antigens (20). With the exception of expression on the 
testis, there are antigens that are mainly expressed by numerous tumors including 
melanoma, which are presented to T cells in the MHC Class I and MHC Class II format 
(20). An example of an antigen that is associated with melanoma and other tumors is 
MAGE. The MHC class I and class II restricted melanocyte differentiation antigens are 
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expressed on normal and neoplastic melanocytes. Melan-A/MART1 is the more 
dominant immunogen among all the melanocyte differentiation antigens. The antigens 
that are largely expressed on tumor cells are recognized only by MHC class I restricted T 
cells and can be present on both normal and cancerous tissues. p15 and p53 are good 
examples of antigens that are largely expressed on tumor cells (20). 
The melanoma specific antigens are presented in a MHC class I format to T cells. 
An important melanoma specific antigen is tyrosinase-related protein-2 (TRP2). If one of 
the common melanoma antigens were very immunogenic, it would possibly be effective 
in a melanoma vaccine (20). However, even though melanoma patients may have a 
cytotoxic T cell response following previous exposure to melanoma antigenic peptides in 
the form of a vaccine, there was no link with clinical responses (21-23). Low survival 
rates have been associated with a lack of lymphoid infiltration (24,25). 
Many cancer cells possess self antigens that the immune system will not 
recognize and attack. Even if cancer cells have some tumor antigens with dominant 
epitopes, it remains difficult to find the right combination of antigens such as melanoma 
antigens to produce an effective melanoma vaccine. Even though tumor associated 
antigens (TAAs) can elicit an immune response, one needs the right combination of 
TAAs for efficacy. MART1 and gp100 are two important TAAs for human melanoma.  
The major problem with controlling the growth of many solid tumors including 
B16.F10 melanoma is that they are poorly immunogenic. Some melanoma tumors 
express CD95L also known as FasL (26-28). Some tumor cells elude the immune system 
by using their CD95L to attach to CD95 receptor on immune cells and induce cell death 
(apoptosis) of the immune cells (29). CD95 and CD95L already exist on B16 melanoma 
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cells. However, exposure to IFN-γ significantly enhanced the expression of CD95 and 
CD95L on B16 cells. B16 cells which posses both CD95 and CD95L are primed for 
apoptosis (29). In addition, B16 cells do not express MHC class II molecules at all. 
However, B16 cells express extremely low quantities of MHC class I (30). Both the 
MHC class I and class II molecules can be expressed on B16 cells once the cells are 
exposed to IFN-γ (30).  
The B16.F10 tumor model is an excellent tumor model to examine the intricacies 
of human tumor development/progression and treatment strategies since the B16. F10 
tumor is poorly immunogenic. Treatment strategies would have to effectively overcome 
the lack of immunogenicity to eradicate the tumor and provide long-term protection 
against recurrence.  
 
Alternative Adjuvant Treatment Strategies for Melanoma 
Interventional treatment options for melanoma other than surgery are relatively 
limited and underscore the need for the development of novel efficacious therapies. Even 
after surgical removal of the primary melanoma, patients who had primary melanoma 
greater than 4 mm or any form of metastasis are at increased risk of tumor recurrence. 
Interferon alpha-2b is administered to patients who have a high risk of melanoma 
recurrence (31,32). The FDA approved the use of high dose interferon alpha for adjuvant 
therapy after surgery in patients with stage IIB and stage III melanoma. Thus far, high 
dose interferon alpha-2b treatment provides significant relapse free survival but cannot 
establish overall survival benefits. Since the FDA approved the use of interferon alpha-
 8
2b, many cancer centers have utilized this therapy. However, there is no widespread 
consensus of using interferon alpha-2b throughout the U.S.  
IL-2 is another alternative treatment for patients with metastatic melanoma (33). 
Even though IL-2 therapy results in rare complete responses (i.e. 8% complete responses 
or complete tumor regressions), it is one of the only treatments for metastatic melanoma. 
Both interferon alpha and IL-2 are given at doses that have a high potential for toxicity. 
Some treatments offer enhanced overall survival for melanoma patients but not 
necessarily regression of the tumors. In the animal model, especially in the B16.F10 
tumor model, significant growth inhibition is customarily the only attainable goal for 
treatment strategies.  
Instead of focusing attention on using immunotherapy to recruit the immune 
system to eradicate tumors, it may be more beneficial to shift attention to delivering an 
agent that will eradicate tumors through intracellular mechanisms and then recruit 
immune cells to establish a long-lasting anti-tumor response. One such agent is the Vpr 
protein, from HIV-1, which causes apoptosis in various cell lines including cancer cells 
(34,35). The other issue concerning eradication of a solid tumor is the choice of the 
delivery mechanism. A well-accepted non-viral delivery mechanism is electroporation. 
Therefore, in this study, in vivo electroporation was used in order to effectively deliver 
plasmid encoding Vpr to B16 solid tumors. 
 
HIV-1 and Vpr 
HIV-1 is the etiological agent of AIDS in humans. HIV-1 is a disease that is 
obtained through contact with infected blood and sexual contact with an infected person. 
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It is a lentivirus which incorporates its provirus into the genome of the host and uses the 
host’s cellular machinery to produce its viral proteins (36). Unlike other retroviruses, 
HIV-1 also has six accessory genes in addition to its customary structural genes, gag, pol, 
and env (36,37). One accessory gene that is conserved throughout HIV-1, HIV-2, and 
SIV is vpr.  
Research has shown that HIV-1 causes cell growth arrest and differentiation in 
cell culture. Following transfection of a HIV-1 plasmid into TE671 embryonal 
rhabdomyosarcoma cells, cell growth arrest occurred within days (38). After almost six 
days, the HIV-1 transfected cells were tremendously enlarged in size, completely viable, 
and did not replicate (38). The transfected TE671cells continued to show viability in vitro 
for at least 3 weeks. Levy et al. (1993) provided the first evidence that HIV-1 has the 
capability of inducing cell cycle arrest without cell death as well as the capacity of 
inducing cell differentiation.  
After various HIV-1 structural genes as well as accessory genes were tested, it 
was found that Vpr was responsible for cell growth arrest and differentiation in vitro. In 
fact, following exposure to an HIV-1 genome which lacked vpr, transfected 
rhabdomyosarcoma cells did not experience growth arrest or substantially differentiate 
(38). To examine whether other transformed cells would undergo growth arrest and 
differentiation, Levy et al. (1993) transfected human and canine osteosarcoma cells with 
vpr plasmid. The vpr-transfected osteosarcoma cells experienced cell growth arrest 
without differentiation. 
The functions of HIV-1 Vpr are diverse. Depending on the cell type, the functions 
of Vpr vary: cell growth inhibition; G2 arrest; influence on tumor growth; differentiation; 
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virus replication in macrophages and non-dividing cells; and transcriptional activation. 
Some of the functions of Vpr are beneficial for the survival of HIV within the host and 
other functions are tailored for dysregulation of cellular processes in cells other than host 
cells i.e. cancer cells. Wong-Staal et al. (1987) made the first assessment that the R open 
reading frame encoded for a protein (39). Wong-Staal et al. (1987) translated vpr in 
bacteria and discovered that approximately forty percent of HIV infected people had 
antibodies against the Vpr protein, demonstrating that a Vpr protein was produced in 
vivo. During in vitro cell culture, virus production is undetectable in HIV-infected 
peripheral blood cells unless the cells are stimulated by antigen, mitogen, or cytokines 
(40-43). vpr augments HIV and SIV replication in T cells and macrophages (44-48). 
Ogawa et al. (1989) provided the first evidence that Vpr may be a positive attribute in 
terms of HIV replication (46). Data demonstrate that HIV-1 vpr is sufficient to cause 
differentiation and growth inhibition in the human rhabdomyosarcoma cells, TE671 (38). 
The vpr-transfected TE671 cells underwent differentiation as demonstrated by the cells 
becoming large in size, developing branched processes, and being multinucleated. It was 
noted that these differentiated cells did not replicate after transfection. The vpr gene also 
causes differentiation and growth inhibition in various cell lines such as 
rhabdomyosarcoma line RD and osteosarcoma line D17 (38). 
Animal Models for HIV-1 
The only animals capable of being infected with HIV-1 are humans and 
chimpanzees. However, there is currently no reliable animal model for a naturally 
occurring HIV-1 infection. Data did show that chimpanzees could be infected with 
relatively low doses of HIV, yet there was no long-term damage to the chimpanzees’ 
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immune systems (37). In a rare occurrence, high viral loads and a CD4+ T cell depletion 
to 100 cell/μl range did arise in one chimpanzee almost a decade after being exposed to 
two different HIV strains (HIV-1SF2 and HIV-1LAV-1b). Due to the fact that chimpanzees 
are an endangered species that are incapable of progressing to disease in a timely manner 
following exposure of virus isolates, they are not sought after as an animal model for 
HIV-1 immunodeficiency (49). 
Researchers have developed transgenic mice that express HIV-1 genes. These 
HIV-1 transgenic mice have copies of proviral DNA in all cells, which characterizes the 
in vivo process of the postintegration stage of the HIV-1 life cycle (37). Transgenic mice 
have viral genes under the direction of cell or tissue-specific promoters. There are Vpr 
transgenic mice. 
 
Functions of Vpr 
Apoptosis 
The C-terminal domain of Vpr has a consequence on the mitochondria as 
evidenced by the expulsion of cytochrome C and apoptosis-inducing factor (AIF) which 
induce apoptosis (50). Also, apoptosis arises from the interaction of Vpr with the adenine 
nucleotide translocator (ANT) which leads to membrane permeabilization of the 
mitochondria (50). Bcl-2 is an anti-apoptotic molecule which impedes mitochondrial pore 
formation by interacting with ANT to hinder the binding of Vpr with ANT (51). 
However, in intact cells, Vpr protein can overcome the anti-apoptotic property of Bcl-2 
(52).  
Vpr is a multifaceted protein that induces apoptosis via a caspase-dependent as 
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well as a caspase-independent mechanism. AIF is a hallmark of the caspase-independent 
approach to apoptosis (53). In contrast to caspase-independent apoptosis, Vpr causes 
apoptosis through caspase-9 activation. Vpr does not operate via the Fas/FasL pathway 
(52). p53 is not a requirement for Vpr-mediated apoptosis even in human tumor cells 
(34,54).  
In rodent cells, Vpr protein induces growth inhibition via G1 arrest and ultimately 
apoptosis in a short span of time which leaves cells that can slowly persist in growth (55). 
G1 arrest as a consequence of Vpr exposure is a more recent concept that is seen in rodent 
cells which have been transfected with Vpr plasmid (55). Throughout the literature 
primate cells have been examined and Vpr- mediated apoptosis has either followed G2 
arrest or has been independent of Vpr induced G2 arrest. Data suggests that Vpr causes 
apoptosis via caspase-9 activity in both rodent and primate cells. The selection of the cell 
cycle arrest phase is a species restricted phenomenon, but not the occurrence of apoptosis 
(55).  
 
Localization of Vpr 
Endogenous Vpr Protein 
There are a few sources for HIV-1 Vpr: virion-borne Vpr, endogenous synthesis 
of Vpr, and extracellular Vpr. Vpr in the serum is most likely bound to either viral Gag or 
anti-Vpr antibodies (56-58). The Gag protein is essential for the assimilation of Vpr 
protein into newly developing viral particles (57-59). It is still a question of whether 
extracellular Vpr occurs due to disintegration of infected cells or to release from infected 
cells (60). 
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Cells that have been transfected with plasmid encoding vpr express Vpr protein 
within the cells at sufficient levels. Apoptosis has been observed in various cell lines such 
as tumor cell lines after exposure to Vpr protein. Previous research has focused on cells 
derived from primates including human cancer cell lines to attest to the apoptotic activity 
induced by Vpr. However, even in rodent cells, Vpr protein causes apoptosis via the 
degradation of mitochondria and the activation of caspase-9 (55). Rodent cells derived 
from hamster and mouse such as BHK and NIH3T3 cells undergo apoptosis after 
transfection with Vpr plasmid (55). 
Extracellular Vpr Protein 
There are various transformed cell lines in which Vpr protein was exported after 
transfection with the vpr gene. These transformed cell lines are T cells (H9, Sup T-1), 
monocytes (HL60,THP-1), muscle cells (TE671, RD), and neuroblastoma cells (SK-N-
MC) (56). There are several studies in which purified intracellular Vpr protein penetrates 
the cells (61,62).  
Bystander Effect 
HIV-1 soluble factors such as Vpr have always played a role in the  
bystander effect in terms of killing non-Vpr expressing cells during an infection. Studies 
have shown various uninfected cells that succumb to apoptosis during HIV infection such 
as uninfected CD4+ T cells, thymocytes, lymph node cells, CD8+ T cells, B cells, 
macrophages, natural killer cells, and dendritic cells (63-77). The Vpr-mediated 
bystander effect is not only demonstrated in primate cell lines or cells involved in active 
infection. Vpr protein induces apoptosis in Vpr -transfected rodent cells as well as non-
transfected rodent cells grown in the same culture (55).  
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Purified Vpr protein can penetrate cells in vitro (61,62). If purified Vpr can 
penetrate cells simply by being in the presence of the cells, there is no reason not to 
speculate that Vpr derived from a plasmid can be secreted from transfected melanoma 
cells within an established tumor to other cells within that tumor. In this manner, the 
enhanced delivery method of intratumoral injection of plasmid encoding Vpr plus 
electroporation could lead to Vpr protein being secreted throughout the tumor and leaving 
a trail of apoptotic cells in its path. Vpr protein can create ion channels in cell membranes 
of live cells (78). Apoptotic attributes occurred in whole cells and purified mitochondria 
after exposure to extracellular Vpr (50,51).  
Expression Level Determines Apoptotic or Anti-Apoptotic Attributes of Vpr 
Even though the majority of studies point to the apoptotic role of Vpr in a variety 
of cell types, there are a minority of studies which indicate an anti-apoptotic role for Vpr. 
During the natural course of HIV-1 infection, it is predicted that Vpr expression is low in 
order to facilitate survival of the virus. The anti-apoptotic aspect was exhibited in the 
early stage of HIV-1 infection (79). Evidence indicates an anti-apoptotic property of Vpr 
when Vpr is expressed at low levels. CD4+ T Jurkat cells which continually expressed 
low quantities of Vpr were able to resist cell death after exposure to apoptosis-inducing 
reagents (80). Also, HEp-2 cells which continually expressed low quantities of Vpr 
demonstrated an anti-apoptotic feature (81). Conversely, evidence demonstrates that high 
Vpr expression causes apoptosis (54,82-85). 
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Electroporation 
In Vitro Electroporation 
Electroporation is a transfection method that uses the application of electric pulses 
(i.e. electric field) to cause transient permeability of the cell membrane and permits drugs 
and plasmids to cross the cell membrane (86,87). DNA was successfully transferred in 
vitro to murine lyoma cells which marked the first gene transfer into mammalian cells 
using electroporation (86,87). Neumann et al. (1982) greatly enhanced the electrically-
mediated uptake of DNA in the murine lyoma cells by better optimizing the electric field 
strength conditions (high electric fields). The optimum field strength for enhanced DNA 
transfer was 8 kV/cm, 5 μs. Further development of this approach led to studies 
demonstrating that electric fields could be used to effectively administer a 
chemotherapeutic reagent to mammalian cells. The investigators used 1200 V/cm to 
deliver chemotherapeutic drugs to B16.F10 cells in vitro (88). In vitro electroporation 
enhanced the cytotoxic impact of chemotherapeutic drugs such as bleomycin and 
cisplatin on various cell lines especially the B16.F10 cells. Today, laboratories use in 
vitro electroporation as a standard procedure for either transfecting cells or transforming 
bacteria with plasmid.  
In Vivo Electroporation  
 
Electrochemotherapy 
Electrochemotherapy (ECT) is the treatment of tumors via the administration of 
chemotherapeutic agents in conjunction with electric pulses. Bleomycin is the preferred 
chemotherapeutic agent that has been administered in conjunction with electroporation in 
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ECT preclinical studies which examined tumor growth inhibition in various solid tumor 
models (89-92). Previous ECT experiments have demonstrated that bleomycin has the 
greatest decrease in drug concentration necessary to elicit an anti-tumor response (93). 
Our laboratory examined an ECT protocol that delivered bleomycin 
intratumorally to B16 tumors as opposed to the traditional intravenous delivery of 
bleomycin prior to electroporation (94). The findings of this study demonstrated that 
intratumoral administration of bleomycin followed by electroporation yields significantly 
increased survival of ECT-exposed mice, B16 tumor growth delay, and high objective 
response rates which were mainly due to complete responses. Also, the intratumoral 
delivery of bleomycin administered between 30 minutes before electroporation and 3 
minutes following electroporation offered a better window of opportunity for optimal 
electrochemotherapy than the previous intravenous method (94). Even with the improved 
intratumoral ECT technique, ECT offers short-term tumor regressions in established B16 
tumors with a high incidence of recurrence by day 25 post-treatment (90,94-96). One 
plausible explanation for tumor-free ECT-exposed mice experiencing tumor recurrence in 
this very aggressive tumor model is that there was residual disease that resulted from 
microscopic tumor cells next to or beneath the original treatment site (94). Usually after 
ECT treatment of subcutaneous B16 melanoma, there is no long-lasting immunity that 
will provide resistance to future tumor challenge (90,94,96).  
Additional research combined the methodologies of intratumoral ECT with 
intratumoral plasmid delivery plus electroporation (95). GM-CSF plasmid plus 
electroporation treatment was performed 24 hours after ECT and resulted in one out of 
eight mice achieving a complete B16 regression and resisted challenge with B16 cells in 
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the opposite flank for an extra 100 days (95). Sustained B16 tumor regressions were also 
obtained following peritumoral treatment with electrochemotherapy combined with IL-2 
plus electroporation. In addition, tumors such as mammary tumors and squamous cell 
carcinoma regressed as a result of treatment with IL-12 plasmid plus ECT (97). The next 
phase of in vivo electroporation was to use electroporation to enhance the delivery of 
plasmid expressing a wide range of proteins but mainly cytokines.  
 
Plasmid DNA Delivery plus Electroporation 
In vivo delivery of plasmids by electroporation has been used to treat tumors in 
animal models. IL-2 or IL-12 plasmid delivered with in vivo electroporation had an 
impact on slowing B16 tumor growth (98). IL-2 or IL-12 plasmid was administered with 
or without electroporation on only one treatment day. IL-2 or IL-12 plasmid plus 
electroporation caused a significant tumor growth delay of about five to fifteen days in 
comparison to IL-2 or IL-12 plasmid intratumorally delivered to the B16 tumor without 
electroporation. Plasmids encoding for IL-12 and IL-18 delivered with electroporation 
inhibited B16 tumor growth in mice (99). When the combination of IL-12 and IL-18 
plasmids was administered to the B16 tumors via electroporation, mice had significant 
longevity as well as significant reduction in tumor volume in comparison with mice that 
were given IL-12 and IL-18 plasmids without electroporation.  
There are only a few studies in which a cytokine expression plasmid has caused 
complete regression of a subcutaneous B16 tumor. Treatment with IL-12 plasmid plus 
electroporation caused established B16.F10 melanoma lesions to completely regress 
which resulted in high cure rates (100,101). The electrode design, the electric field 
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strength, and the treatment days were the major parameters involved in the anti-
proliferative activity of the electrically-mediated delivery of IL-2, IL-12, and IL-12/IL-18 
plasmids. Therefore, the studies in which over 40% of the mice had complete regression 
resulted from the use of a penetrating electrode that rotated 1500 V/cm around the tumor 
on multiple treatment days (100,101). The aforementioned parameters will have to be 
determined in any future electrogenetherapy protocol.  
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Objectives 
 
 
The HIV-1 Vpr protein has a variety of roles in cell cycle arrest and apoptosis of 
numerous cell types especially cancer cell lines in vitro. However, the in vivo activity of 
HIV-1 Vpr has not been closely examined in terms of tumor growth inhibition and tumor 
regression in a solid tumor model particularly in the context of a non-viral delivery 
method. For this reason, studies were initiated to examine the effects of electrically-
mediated intratumoral Vpr plasmid delivery into subcutaneous B16 melanoma in 
C57/BL6 mice. The B16.F10 melanoma grows very aggressively and has a deficiency in 
MHC I molecules which makes this tumor poorly immunogenic (29). Therefore, a 
successful Vpr plasmid plus electroporation treatment regimen against B16 melanoma 
should work at the early time points after initiation of treatment and cause long-term 
tumor-free survival in treated mice.  
The hypothesis of this work: Intratumoral delivery of a Vpr expression plasmid 
administered with in vivo electroporation will lead to growth inhibition and regression of 
established B16.F10 melanoma in syngeneic C57BL/6 mice.  
This is the first description of the ability of a plasmid expressing HIV-1 Vpr, 
when delivered by in vivo electroporation, to cause complete regression of an aggressive 
metastatic tumor such as melanoma. In order to characterize the anticancer mechanism of 
Vpr, the following aims have been proposed. 
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Specific Aim 1 
To Determine the Optimal pVpr Dosage and Electroporation Parameters Required for 
Tumor Reduction 
Electrogenetherapy enhances protein expression following delivery of a plasmid 
that encodes the protein of interest. In this manner, Vpr protein would be more effectively 
expressed once pVpr has been administered by in vivo electroporation. Several dosages 
ranging from 25 μg to 200 μg of pVpr in combination with electroporation will be 
examined in order to determine the appropriate dosage of pVpr that causes optimum 
tumor growth inhibition and/or regression. In addition to the proper pVpr dosage, the 
optimum electroporation parameters will be incorporated into the protocol. After 
appropriate treatment, tumor growth rates will be evaluated based on tumor volume 
calculations. In order to substantiate that Vpr protein is contributing to the tumor 
inhibition and/or regression, it will be necessary to examine Vpr expression following 
electrically mediated delivery of pVpr to tumors. Vpr protein will be detected by 
immunohistochemical staining of tumors excised at time points prior to regression. 
 
Specific Aim 2 
To Elucidate a Mechanism Regarding the Ability of Vpr to Inhibit Tumor Growth In Vivo 
Previous in vitro studies have shown that Vpr induces apoptosis in a variety of 
cancer cells; similarly pVpr plus electroporation may reduce B16 tumor volume in mice 
through induction of apoptosis. The elucidation of the tumor inhibitory mechanism will 
involve the use of the TUNEL assay. The TUNEL assay will be used to determine 
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apoptosis in tumor-bearing mice after the mice have received various pVpr treatment 
regimens. 
 
Specific Aim 3 
To Investigate whether pVpr Induces an Immune Response, which would allow the 
Treated Mice to be Resistant to Tumor Challenge 
Previous research has demonstrated that following electrically- mediated delivery 
of certain chemotherapeutic agents or cytokine expressing plasmids, the B16.F10 tumors 
recur at the original site of regression. However, there have been successful treatments 
administered with electroporation that have yielded long-term complete B16 tumor 
regression without tumor recurrence, cured mice. In the scenarios in which long-term 
tumor regression occurs, mice are challenged with parental B16.F10 cells on the flank 
opposite to the one which was originally treated. If cured mice are able to resist challenge 
with parental cells then an immune system component may be associated with the 
treatment. If any mice are cured following treatment with pVpr plus electroporation, they 
will be injected with B16.F10 melanoma cells on the opposite flank and monitored for 
tumor growth at the challenge site.  
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Methods 
 
Mice 
 C57BL/6 mice, the murine strain syngeneic for the B16.F10 melanoma tumor cell 
line, were used in this study and were purchased from the National Cancer Institute 
(NCI). Mice were housed and maintained during this study in accordance with AALAM 
guidelines. 
 
Tumor Cells 
 The B16.F10 murine melanoma cell line (CRL 6475) was originally purchased 
from ATCC and was maintained for studies as monolayers in culture in 90% McCoy’s 
medium supplemented with 10% fetal bovine serum (FBS). For the preparation of single 
cell suspensions, monolayer of cells were detached from flasks using trypsin-EDTA 
(0.05% trypsin-0.53 mM EDTA), centrifuged, washed and resuspended at the proper 
concentration for injection in the tumor induction experiments described below. 
 
Subcutaneous Tumor Implantation and Measurements 
Tumors were induced by subcutaneous injection of 1x106 B16.F10 cells which 
were prepared as described above (viability of cells was greater than 90% as measured by 
Trypan blue exclusion) into the left flanks of C57BL/6 mice. Tumors were allowed to 
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grow to the appropriate size of at least 29 mm3 but could be larger (depending on the 
experiment) before commencement of the treatment regimen. A tumor volume of at least 
29 mm3 has been determined to be an ideal minimal size for intratumoral injection since 
the administered treatment volume is retained effectively within the lesion with no 
significant leakage, providing confidence that the entire dose had been administered. 
Tumor volumes were measured before and at periodic intervals following treatment using 
a digital caliper by measuring the longest diameter (a) and the next longest diameter (b) 
perpendicular to (a). Using those measurements the tumor volume was calculated by the 
formula: V = ab2x π/6. The mice were followed in each experiment until the defined end-
point was reached or until tumor volume was determined to be 1300 mm3 (at which point 
any mice had usually succumbed to tumor burden or were euthanized due to the size of 
the tumor).  
 
Plasmid DNA 
 The pVpr was a gift from Dr. David Weiner. pVpr encodes the Vpr protein under 
the control of a CMV promoter. pcDNA3.1 is the non-coding control plasmid 
(Invitrogen). Plasmids were prepared using an endotoxin-free procedure (Qiagen, 
Valencia, CA) and suspended in sterile physiological saline.  
 
Anesthesia 
 Mice were anesthetized by putting them in an induction chamber permeated with 
2.5% isoflurane and 97.5% oxygen. Anesthesia was supplied to the mice via a rodent 
mask.  
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Intratumoral Delivery of Plasmid plus In Vivo Electroporation 
Tumors were treated intratumorally with the specified dosage of the Vpr plasmid 
(pVpr) or control / backbone plasmid vector (pcDNA3.1) depending on the experiment. 
Subsequently, tumors from the appropriate groups were subjected to in vivo 
electroporation using a custom-made applicator containing 6 penetrating electrodes that 
was inserted into the tissue around the tumor. Depending on the treatment group, electric 
pulses were administered using a BTX T820 pulse generator (BTX/Harvard Apparatus, 
Hollister, MA) and autoswitcher (Genetronics, San Diego, CA). The optimum 
electroporation parameters were 1500 V/cm, 100 μs, 6 pulses. These electroporation 
parameters were previously described in other studies by our group and were selected 
because of their less stringent parameters coupled with the ability to elicit a significant 
biological effect.  
Treatments were administered on selected days depending on the electroporation 
protocol used in the experiment. For the treatment groups P+ or P– indicates with or 
without treatment with the pVpr and E+ or E- indicates with or without electroporation, 
respectively. V+ or V- indicates with or without the control “backbone” vector 
(pcDNA3.1), respectively.  
The mean tumor volume was calculated for each group at selected time points 
after the treatment regimen. Additional quantitative measurements made during the study 
were fold increase in tumor volume compared to day 0 as well as percent of mice 
undergoing complete tumor regression coupled with long-term survival. 
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Immunohistochemistry 
 Tumors were excised at selected time points after treatment and snap frozen. 
Tumors were sliced into 5 μm sections. Sections were fixed in ice cold methanol for 10 
minutes. Non-specific antigens were blocked in 3% BSA/PBS/Triton X-100 for one hour 
at room temperature. Sections were blocked in mouse BD Fc Block in 3% 
BSA/PBS/Triton X-100 for one hour (BD Pharmingen). The sections were stained with 
the polyclonal Vpr antibody (diluted 1:2000) for one hour at room temperature. Then 
sections were incubated with Alexa Fluor 594, a PE-conjugated secondary antibody 
(diluted 1: 8000) (Molecular Probes, Inc.). Sections were stained with Hoechst to identify 
the nuclei. The sections were visualized using a fluorescent microscope. 
 
TUNEL Assay 
 For each treatment group, the same tumor sample was used to prepare consecutive 
sections for immunohistochemistry and the TUNEL assay. TUNEL refers to Terminal 
transferase dUTP nick end labeling which allows for the detection of apoptosis. Sections 
were fixed in ice cold methanol for 10 minutes. Apoptosis was assessed using the TACS 
in-situ kit TdT-Fluorescein (R & D Systems). Tumor sections were treated with 
proteinase K for one hour at room temperature. A TUNEL reaction mixture containing 
TdT biotinylated nucleotides was added to each section and incubated in a humidified 
chamber for one hour at 37 °C. The biotinylated nucleotides were incubated with a 
streptavidin-fluorescein conjugate and visualized using a fluorescent microscope. The 
sections were also stained with Hoechst. 
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Statistical Analysis 
Statistical analysis was conducted using the Student’s t-test. p < 0.05 was 
determined to be statistically significant. 
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Results 
 
Specific Aim 1 
To Determine the Optimal pVpr Dosage and Electroporation Parameters  
Required for Tumor Reduction 
 
Preliminary Studies on Vpr Expression and B16 Tumor Growth Inhibition 
Numerous preliminary experiments were conducted in order to set parameters to 
ascertain pivotal information that would lay the foundation for addressing the specific 
aims of this research project. In many instances, the total number of animals used in the 
preliminary experiments was small because these experiments were merely designed to 
test a hypothesis such as whether there would be protein expression after electrically-
mediated delivery of plasmid or whether B16 tumor growth inhibition would occur as a 
consequence of electrically-mediated delivery of pVpr. The experiments for the optimal 
pVpr regimens have higher n values ranging from 10-14 mice after duplicate experiments 
were conducted.  
The preliminary experiments addressed a wide range of issues such as the 
selection of the most effective electroporation parameters for delivery of pVpr and Vpr 
protein expression. The initial experiments involved selecting the parameters for the 
appropriate pVpr dosage, effective electroporation conditions, elevated Vpr expression, 
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and optimal treatment days that would cause the most reduction of B16 tumor in the 
mouse model. In particular, B16 tumors were treated with dosages ranging from 25 μg to 
200 μg of pVpr plus electroporation in order to determine which dosage would yield the 
most tumor growth inhibition. Four different electroporation parameters were examined 
in order to determine which parameters would cause the highest Vpr protein expression. 
The electroporation parameters were as follows: 100 V/cm, 150 ms; 200 V/cm, 20 ms; 
800 V/cm, 5 ms; and 1500 V/cm, 100 μs. Similar electroporation parameters that were 
used to confirm Vpr expression were also used to determine which parameters would 
effectively deliver pVpr to the B16 tumor.  
Another key factor in establishing a pVpr plus electroporation treatment protocol 
was the schedule of treatment days. Preliminary experiments involved using the initial 
treatment regimen in which treatments were administered on days 0 & 4. Following some 
revisions in the schedule, tumor-bearing mice were later treated daily or on alternating 
treatment days to obtain more tumor reduction and/or tumor regression than the day 0 & 
4 treatment regimen. The individual parameters examined in the preliminary experiments 
to effectively deliver an optimal pVpr dosage with the appropriate electroporation 
conditions on particular treatment days would be combined for future experiments to 
electrically-mediate the delivery of pVpr and yield the highest Vpr expression along with 
tumor reduction and/or regression. The key for the following experiments: + or - = with 
or without, P= pVpr, V= pcDNA3.1 (non-coding vector), and E = electroporation. 
Confirmation of Intratumoral Expression of Vpr in B16 Melanoma Lesions 
Initial studies were conducted to confirm Vpr expression and to determine the 
kinetics of protein expression. As part of this evaluation, different electroporation 
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parameters (i.e. field strength and pulse width) were tested. Tumor-bearing mice were 
treated with a single injection of pVpr followed by electroporation. One-hundred 
micrograms of pVpr was chosen to study the time course for Vpr protein expression. 
Following treatment, four tumors per group were excised at day 2 and day 4. The tumors 
were subjected to immunohistochemistry using the polyclonal Vpr antibody. The 
treatment groups were as follows: Group 1: P-E+ saline 1500 V/cm, 100 μs; Group 2: 
P+E- 100 μg pVpr; Group 3: P+E+ 100 μg pVpr 100 V/cm, 150 ms; Group 4: P+E+ 100 
μg pVpr 200 V/cm, 20 ms; Group 5: P+E+ 100 μg pVpr 800 V/cm, 5 ms; Group 6: P+E+ 
100 μg pVpr 1500 V/cm, 100 μs. Figure 1 depicts intratumoral Vpr staining of a tumor 
excised on day 2 post-treatment. At day 2 post-treatment, the saline + 1500 V/cm, 100 μs 
treated tumors have non-specific staining (Figure 1A). There is Vpr expression after 
delivery of pVpr without electroporation (Figure 1B). In comparison to pVpr delivered 
without electroporation, there is greater distribution of Vpr protein throughout the tumor 
section following delivery of pVpr plus 1500 V/cm, 100 μs (Figure 1F). The other 
electroporation conditions yielded minimal Vpr protein expression (Figure 1C-E). Figure 
2 depicts intratumoral Vpr staining of a tumor excised on day 4 post-treatment. At day 4 
post-treatment, there is only non-specific staining for the tumors treated with saline plus 
1500 V/cm, 100 μs (Figure 2A). The tumors treated with pVpr without electroporation 
did not have Vpr expression at day 4 post-treatment (Figure 2B). At day 4, there is still 
no detectable Vpr protein expression for any of the other electroporation conditions 
(Figure 2C-E). By day 4 post-treatment, the tumors treated with 100 μg pVpr plus 1500 
V/cm, 100 μs no longer demonstrate Vpr protein expression (Figure 2F).   
  
 
 
Figure 1. B16.F10 Intratumoral Immunohistochemical Staining with Vpr Antibody on 
Day 2 Post-Treatment. All Fields Examined at 20X Magnification. (A) P-E+ Saline 1500 
V/cm, 100 μs; (B) P+E- 100 μg pVpr; (C) P+E+ 100 μg pVpr 100 V/cm, 150 ms; (D) 
P+E+ 100 μg pVpr 200 V/cm, 20 ms; (E) P+E+ 100 μg pVpr 800 V/cm, 5 ms; (F) P+E+ 
100 μg pVpr 1500 V/cm, 100 μs. Representative Tumor of Four Tumors. 
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 Figure 2. B16.F10 Intratumoral Immunohistochemical Staining with Vpr antibody on 
Day 4 Post-Treatment. All Fields Examined at 20X Magnification. (A) P-E+ Saline 1500 
V/cm, 100 μs; (B) P+E- 100 μg pVpr; (C) P+E+ 100 μg pVpr 100 V/cm, 150 ms; (D) 
P+E+ 100 μg pVpr 200 V/cm, 20 ms; (E) P+E+ 100 μg pVpr 800 V/cm, 5 ms; (F) P+E+ 
100 μg pVpr 1500 V/cm, 100 μs. Representative Tumor of Four Tumors. 
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The electroporation parameter 1500 V/cm, 100 μs was chosen as the best 
electroporation parameter because it yielded the highest protein expression at day 2 post-
treatment. Therefore, 1500 V/cm, 100 μs was used in order to determine the appropriate 
pVpr dosage that would cause tumor reduction after delivery of pVpr with 
electroporation. 
B16 Growth Inhibition Following pVpr plus Electroporation Treatments on Day 0 and 
Day 4 
Initial studies were conducted to examine tumor reduction following the selected 
regimen of treatment on day 0 and day 4. In the context of day 0 and day 4 treatments, it 
was necessary to determine which pVpr dosage would be the most efficacious in 
reducing B16 tumor volume. Tumor-bearing mice were treated with pVpr dosages 
ranging from 25 μg to 200 μg administered with or without electroporation. Treatments 
were administered on Day 0 and Day 4. The mice in the electroporation groups received 
1500 V/cm, 100 μs. The groups were as follows: Group 1: No Treatment; Group 2: P+E- 
25 μg pVpr; Group 3: P+E+ 25 μg pVpr; Group 4: P+E- 50 μg pVpr; Group 5: P+E+ 50 
μg pVpr; Group 6: P+E- 100 μg pVpr; Group 7: P+E+ 100 μg pVpr; Group 8: P+E- 200 
μg pVpr; Group 9: P+E+ 200 μg pVpr; Group 10: V+E- 200 μg pcDNA3.1; and Group 
11: V+E+ 200 μg pcDNA3.1. The mean tumor volumes for the groups ranged from 32-
54 mm3.  
The mean fold increase values for pVpr +E+ treated tumors were reduced in 
comparison to some of the other treatment groups (Figure 3A and Figure 3B). Day 15 is  
the end point for the mean fold increase curve because this is the last time point at which 
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a majority of untreated mice were alive for analysis. The mean fold increase values were 
27.44, 17.81, 12.67, 27.81, and 9.01 for mice treated with P+E- 25 μg pVpr, P+E- 50 μg  
pVpr, P+E- 100 μg pVpr, P+E- 200 μg pVpr, and V+E- 200 μg pcDNA3.1, respectively 
(Figure 3A). The mean fold increase value for untreated mice was 24.58. The mean fold 
increase values for mice treated with P+E+ 25 μg pVpr, P+E+ 50 μg pVpr, P+E+ 100 μg 
pVpr, P+E+ 200 μg pVpr, and V+E+ 200 μg pcDNA3.1 were 16.63, 9.36, 7.89, 10.05, 
and 11.99, respectively (Figure 3B). By day 15, the group that received P+E+ 100 μg 
pVpr had the lowest mean fold increase value (i.e. 7.89) when compared to untreated 
mice as well as all other treatment groups. At day 15 post-treatment, the mice treated 
with 100 μg pVpr plus electroporation had a significant reduction in tumor volume (p < 
0.05) in comparison to untreated mice and mice treated with 25 μg pVpr without 
electroporation. A significant difference in tumor reduction could not be established 
between any of the electroporation groups. 
Even though a difference in treatment efficacy could not be established between 
the electroporation groups treated with various dosages of pVpr+ E+ (25 μg to 200 μg  
pVpr) or pcDNA+E+ (200 μg), the group that received 100 μg pVpr +E+ was the only 
group that had significant tumor reduction compared to untreated mice. Therefore, the 
100 μg pVpr dosage with electroporation was further evaluated in the following growth 
inhibition studies in order to enhance the growth inhibitory effect.  
As a follow-up to the initial study in which Vpr protein expression was examined 
after utilizing various electroporation parameters, electroporation parameters were further 
evaluated for the ability to induce tumor growth attenuation. Treatments were conducted 
  
Figure 3A. Various pVpr Dosages Administered without Electroporation to B16 
Melanoma  
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Figure 3B. Various pVpr Dosages Administered with Electroporation to B16 Melanoma
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on day 0 and day 4. Average tumor volumes ranged from 29-47 cubic millimeters. There 
were six mice per group. The groups were as follows: Group 1: P-E+ saline with 1500 
V/cm, 100 μs (electric pulses only); Group 2: P+E- 100 μg pVpr; Group 3: P+E+ 100 μg 
pVpr 100 V/cm, 150 ms; Group 4: P+E+ 100 μg pVpr 200 V/cm, 20 ms; Group 5: P+E+ 
100 μg 800 V/cm, 375 μs; Group 6: P+E+ 100 μg pVpr 1500 V/cm, 100 μs. The mice 
that were treated with only electric pulses had a mean survival time of 14.33 days. Mice 
that were treated with 100 μg pVpr plus 1500 V/cm, 100 μs had a mean survival time of 
18.17 days. The group that received 100 μg pVpr plus 1500 V/cm, 100 μs lived 
significantly (p<0.05) longer than mice given electric pulses only and mice that received 
100 μg pVpr without electroporation (Figure 4). The remaining treatment groups had 
mean survival times of 14, 15, and 15.50 days for 100 V/cm, 150 ms; 200 V/cm, 20 ms; 
and 800 V/cm, 375 μs, respectively.  
At the early time point of day 8, the 100 μg pVpr plus 1500 V/cm, 100 μs treated 
tumors had the lowest tumor volumes compared to tumors treated with 100 μg pVpr 
without electroporation and all the other 100 μg pVpr with electroporation groups (Figure 
5). The tumors treated with 100 μg pVpr without electroporation had lower tumor 
volumes than all the other 100 μg pVpr with electroporation groups at this early time 
point. By day 15 post-treatment the mean fold increase values for the pVpr plus 1500 
V/cm group were similar to the other pVpr plus electroporation conditions. 
In terms of increasing survival time for tumor-bearing mice, 100 μg of pVpr 
delivered with 1500 V/cm, 100 μs 6 pulses of electroporation worked better than its 
counterpart without electroporation and electric pulses alone. In fact, there was enhanced 
  
Figure 4. Percent Survival Curve for Tumor-Bearing Mice Treated with pVpr plus 
Various Electroporation Parameters 
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Figure 5. B16 Tumor Growth Responses to pVpr Delivered with Various Electroporation 
Parameters 
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gene expression in tumors treated with 100 μg pVpr plus 1500 V/cm in comparison to 
tumors treated with 100 μg pVpr without electroporation. At the early time points the 
other electroporation conditions offered the same tumor growth inhibition as the electric 
pulses alone (1500 V/cm, 100 μs). Taken together with the immunohistochemical 
staining, this data suggests that the other electroporation conditions did not provide gene 
expression perhaps because these conditions did not overcome the threshold level that 
would allow for efficient gene delivery. Therefore, the other electroporation parameters 
did not provide enough pVpr for efficient Vpr expression to slow tumor growth. 
The 1500 V/cm electroporation condition had the greatest impact on tumor 
reduction from the onset of the experiment to day 15 post-treatment. It took 15 to 18 days  
for 100 μg of pVpr plus 1500 V/cm treated tumors to grow to the same size as the tumors 
in the other pVpr plus electroporation conditions. Therefore, it would be best to use 1500 
V/cm, 100 μs as the electroporation parameter for future experiments to obtain efficient 
gene expression and apoptosis.  
To further evaluate and confirm the growth inhibition following delivery of pVpr 
with the 1500 V/cm, 100 μs pulsing conditions, another experiment was performed. 
Treatments were administered on Day 0 and Day 4. Initial tumor volumes ranged from 37 
– 42 cubic millimeters. There was an n=7 for each group. The groups were as follows: no 
treatment; 25 μg pVpr+E- ; 25 μg pVpr+E+; 100 μg pVpr+E-; 100 μg pVpr+E+; 100 μg 
pcDNA3.1+E-; 100 μg pcDNA3.1+E+; and saline+ E+. By day 7 post-treatment, the 
mice treated with either dosage of pVpr+E+ or pcDNA+E+ had lower tumor volumes 
than all the other treatment groups including the saline+E+ group. Day 21 was chosen as 
 40
the end point for tumor growth analysis because this is the last day at which untreated 
mice were still alive for inclusion in the analysis. The untreated tumors grew so 
aggressively that all these mice were overcome by tumor burden. By day 21 post-
treatment, the mean fold increase value was 12.21 for the 100 μg pVpr+E+ group. In 
contrast, on day 21, the mean fold increase value was 34.98, 31.38, 45.20, 18.24, and 
72.60 for the groups 25 μg pVpr+E-, 25 μg pVpr+E+, 100 μg pVpr+E-, 100 μg 
pcDNA3.1+E+, and untreated mice, respectively (Figure 6). The 100 μg pcDNA3.1+E- 
group and the saline +E+ group were dead after day 18 and were not included in this  
analysis. Therefore, by day 21, the 100 μg pVpr+E+ treatment group had the largest 
reduction in tumor volume in comparison to the other treatment groups.  
Even though the 100 μg pVpr+E+ treated mice had the largest reduction in tumor 
volume during the earlier time points, these tumor reductions did not result in high 
percentages of long-term complete tumor regressions at latter time points. Of the mice 
that were previously treated with 100 μg pVpr+E+, 1 out of 7 mice had complete tumor 
regression for over 100 days. Interestingly, 2 out of 7 mice treated with 100 μg 
pcDNA3.1+E+ also had complete tumor regression for over 100 days. This type of long- 
term regression has been previously reported by our group after mice were treated with a 
non-coding vector plus electroporation conditions (800 V/cm, 5 ms, 10 pulses) other than 
the ones used in the current experiment. However, this preliminary data demonstrated 
that intratumoral delivery of 100 μg pVpr consistently slowed B16 tumor growth and 
resulted in a long-term complete tumor regression. The results of this preliminary 
experiment warranted further investigation of the influence of 25μg pVpr+E+, 100 μg 
  
 
Figure 6. B16 Tumor Growth Inhibition Following Treatment with pVpr plus 
1500 V/cm, 100 μs 
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pVpr+E+, and 100 μg pcDNA3.1 +E+ on B16 growth and regression after day 0 and day 
4 treatment. In addition, the anti-proliferative effects of Vpr protein warranted further 
investigation into the optimization of the frequency of treatment days.  
Treatment with pVpr plus Electroporation on Four Treatment Days 
The anti-proliferative effects of Vpr protein were further investigated by 
increasing the frequency of treatment days as well as re-evaluating the range of pVpr 
dosages that would lead to tumor growth inhibition in the context of these additional 
treatment days. To maximize B16 tumor reduction, an experiment was conducted to treat 
tumor-bearing mice with various doses of pVpr ranging from 25 μg to 100 μg pVpr 
administered with or without electroporation on four treatment days (i.e. days 0, 4, 7, & 
11). The appropriate non-coding control plasmid with electroporation, pcDNA3.1, was 
used at the 100 μg concentration. There were seven mice per group. The electroporation 
parameters were 1500 V/cm, 100 μs. The treatment groups were as follows: Group 1: No 
treatment; Group 2: P+E- 25 μg pVpr; Group 3: P+E+ 25 μg pVpr; Group 4: P+E- 50 μg 
pVpr; Group 5: P+E+ 50 μg pVpr; Group 6: P+E- 100 μg pVpr; Group 7: P+E+ 100 μg 
pVpr; Group 8: V+E- 100 μg pcDNA3.1; Group 9: V+E+ 100 μg pcDNA3.1. 
Since there were no complete tumor regressions or partial tumor regressions in 
this experiment, the mean tumor doubling time, mean fold increase in tumor volume, and 
the mean survival time were determined. The untreated mice had a mean tumor doubling 
time of 7.67 days. The mice that received 25 μg pVpr or 50 μg pVpr without 
electroporation had mean tumor doubling times of 6.71 and 6.67 days, respectively. The 
mice that received 100 μg pVpr without electroporation and 100 μg pcDNA.3.1 without 
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electroporation had mean tumor doubling times of 8.14 and 9.86 days, respectively. The 
mice that were exposed to 50 μg pVpr with electroporation had a mean tumor doubling  
time of 13.71 days. The mice that were exposed to 100 μg pcDNA.3.1 plus 
electroporation had a mean tumor doubling time of 13.14 days. The mice treated with 100 
μg pVpr plus electroporation had a mean tumor doubling time of 12.83 days. 
Mice that received pVpr or pcDNA3.1 plus electroporation had a reduction in 
tumor volume. Day 15 post-treatment is the end point for the mean fold increase curve 
because this was the last time point at which more than 40% of untreated mice could be 
included for accurate analysis. At day 15, the untreated mice had a mean fold increase of 
15.71. At day 15, the mean fold increase value for mice treated with P+E- 25 μg pVpr, 
P+E- 50 μg pVpr, P+E- 100 μg pVpr , and V+E- 100 μg pcDNA3.1 was 13.08, 20.19, 
18.48, and 15.46, respectively. Also at day 15, the mean fold increase value for mice 
treated with P+E+ 25 μg pVpr, P+E+ 50 μg pVpr, P+E+ 100 μg pVpr, and V+E+ 100 μg 
pcDNA3.1 was 5.18, 4.35, 4.75, and 5.14, respectively (Figure 7). 
Some of the treatment regimens that incorporated electroporation had an impact 
on mean survival time of tumor-bearing mice. Untreated mice had a mean survival time 
of 14.14 days. Mice treated with P+E- 25 μg pVpr, P+E- 50 μg pVpr, P+E- 100 μg pVpr, 
and V+E- 100 μg pcDNA3.1 had mean survival times of 16, 13.71, 18.86, and 17.43, 
respectively.  Mice treated with P+E+ 25 μg pVpr, P+E+ 50 μg pVpr, P+E+ 100 μg 
pVpr, and V+E+ 100 μg had mean survival times of 18.71, 25.86, 21.57, and 20.29. Mice 
that were treated with P+E+ 50 μg pVpr and P+E+ 100 μg pVpr were the only groups 
that lived significantly (p< 0.05) longer than untreated mice. 
  
 
Figure 7. B16 Tumor Growth Attenuation Following Various Dosages of pVpr plus 
Electroporation 
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Consecutive Treatment Days versus Alternating Treatment Days with pVpr plus 
Electroporation 
Since subcutaneous B16 tumors grow so aggressively, it was necessary to have 
treatments occur at closer intervals to combat tumor growth that would occur between the 
treatment days that were previously mentioned such as treatment days 0, 4, 7, and 11. As 
part of the evaluation of the anti-proliferative effects of Vpr protein, pVpr plus 
electroporation treatments were administered to tumor-bearing mice to determine 
whether consecutive treatment days or alternating treatment days would lead to enhanced 
tumor growth inhibition. Mice were treated with 100 μg pVpr with 1500 V/cm, 100 μs. 
The consecutive treatment days were days 0 and 1. The alternating treatment days were 0 
and 2. There was no difference in mean tumor doubling time since both treatment 
regimens resulted in a mean tumor doubling time of 8 days. The mean fold increase curve 
illustrates the first 11 days because this is the last time point at which the majority 
of mice were still alive to obtain an accurate assessment of statistical analysis. In 
accordance with the mean fold increase data, at the early time points, the consecutive 
treatment regimen caused more reduction in tumor volume than the alternating treatment 
regimen. However, by day 8 and 11 post-treatment, the alternating treatment appears 
more effective in reducing tumor volume (Figure 8). The preliminary experiments which 
examined the effects of delivering pVpr with electroporation on alternating treatment 
days resulted in tumor growth inhibition. 
 
 
 
  
 
Figure 8. Growth Attenuation in B16 Tumor Volume Following Treatment with pVpr 
plus Electroporation on Alternating Treatment Days 
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Therapeutic Benefit of Daily Treatment with pVpr plus Electroporation 
In accordance with the data demonstrating the beneficial aspects of tumor 
reduction following a consecutive treatment regimen with pVpr plus electroporation, it 
was necessary to determine whether there would be additional benefits in extending the 
consecutive treatment regimen to include more days. A combination of experiments  
were conducted to determine whether daily treatment (i.e. day 0- day 7) would lead to 
enhanced tumor reduction and regression after tumor-bearing mice were exposed to 100 
μg pVpr plus electroporation. However, this experiment had additional treatment groups 
which varied in the days and frequency of treatment administration including the original 
treatment regimen of day 0 and day 4. The results represent a combination of two 
experiments that were conducted to give a total n of five mice per group with the 
exception of the untreated mice and the pcDNA +E+ treated mice. The 100 μg 
pcDNA3.1 + E+ group was included in the second experiment as a control group and had 
an end-point of 62 days. The treatment groups were as follows: Group 1: P-E+ 1500 
V/cm, 100 μs saline twice daily (treatment days 0-7); Group 2: P+E+ 100 μg pVpr 1500 
V/cm, 100 μs twice daily (treatment days 0-7); Group 3: P+E+ 100 μg pVpr 1500 V/cm, 
100 μs once daily (treatment days 0-7); Group 4: P+E+ 100 μg pVpr 1500 V/cm, 100 μs 
on days 0, 2, 4, & 6; Group 5: P+E+ 100 μg pVpr 1500 V/cm, 100 μs on days 0 & 4; and 
Group 6: No treatment (n=3); and Group 7: V+E+ 100 μg pcDNA3.1 1500 V/cm, 100 μs 
once daily (n= 4). 
The various pVpr +E+ treatment regimens extended the lifespan of treated mice. 
The untreated tumors grew very aggressively. The mean survival time for untreated mice  
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was 11.67 days. Mice treated with 100 μg pVpr plus electroporation twice daily and once 
daily had a mean survival time of 146.20 and 122, respectively. Mice treated with 100 μg 
pVpr +E+ on days 0 & 4 and mice treated with 100 μg pVpr +E+ on days 0, 2, 4, & 6 had 
mean survival times of 28 and 55.60 days, respectively. All of the mice treated once daily 
with 100 μg pcDNA3.1 +E+ had a mean survival time of 62 days.  
Mice treated with electric pulses administered twice daily had a mean survival 
time of 26.80 days. Mice treated with 100 μg pVpr +E+ twice daily lived significantly 
longer (p<0.05) than mice treated with 100 μg pVpr +E+ on days 0, 2, 4, & 6; 100 μg 
pVpr +E+ on days 0 & 4; saline +electric pulses twice daily; and untreated mice. Mice 
treated with 100 μg pVpr +E+ once daily lived significantly longer (p<0.05) than mice 
treated with 100 μg pVpr +E+ on days 0 & 4; saline +electric pulses twice daily; and 
untreated mice. Mice treated with 100 μg pVpr +E+ on days 0 & 4 lived significantly 
longer (p<0.05) than untreated mice. There is no statistical difference between the mean 
survival times for the mice treated with pVpr +E+ twice daily or once daily.  
Day 21 post-treatment is the end-point for the mean fold increase curve because 
this is the last time at which a majority of the saline plus electroporation treated mice 
were alive. At day 21 post-treatment, the mice that were treated with 100 μg pVpr plus  
electroporation either twice daily or once daily had significant tumor reduction (p<0.05) 
in comparison to mice treated with only electric pulses twice daily (Figure 9). There is no 
difference between any of the other pVpr+ E+ treatment groups in terms of mean fold 
increase values. However, there are differences in pVpr +E+ treatment regimens in terms 
of complete tumor regressions. One hundred days after initial treatment, 80% of mice 
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receiving either once daily or twice daily intratumoral delivery of 100 μg pVpr with 
electroporation were tumor-free. These mice were considered cured. Following 
intratumoral delivery of pVpr plus electroporation on Days 0, 2, 4 & 6, one tumor-
bearing mouse was cured. Tumor volume continued to decrease until all four of the 
pcDNA3.1+ E+ treated mice had complete regressions by day 18 post-treatment (Figure 
9). The daily pVpr +E+ treatment regimens were more effective than the original pVpr + 
E+ treatment regimen of day 0 & day 4 in terms of increasing the longevity of mice as 
well as inducing a higher percentage of complete regressions. 
Intratumoral pVpr plus Electroporation Administered with a Revised Alternating 
Treatment Regimen 
Daily treatments offered 80 – 100% complete tumor regressions irrespective of 
pVpr + E+ or pcDNA +E+ treatment. Therefore, it was necessary to devise an alternative 
treatment regimen that would offer tumor growth inhibitions, complete tumor 
regressions, and distinction between pVpr and pcDNA effects. Since the original 
alternating pVpr plus electroporation treatment administered on days 0 & 2 yielded 
growth inhibition, the concept of administering pVpr with electroporation on alternating 
treatment days was revisited with an additional treatment day included. Mice were treated 
with 100 μg pVpr plus electroporation on Days 0, 2, and 4. 100 μg pcDNA3.1 plus 
electroporation was used as a control. The electroporation parameters were 1500 V/cm, 
100 μs. Each group had an n=3. The mice treated with 100 μg pVpr plus electroporation 
experienced both a partial response and complete response towards the treatment. From 
days 9 through 16 post-treatment, one mouse treated with pVpr plus electroporation had 
complete tumor regression until the tumor recurred. There was a slight pcDNA +E+ 
  
Figure 9. Daily Treatment with 100 μg pVpr plus Electroporation Leads to Enhanced 
Tumor Reduction 
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effect observed at later time points as one pcDNA +E+ treated mouse had complete 
tumor regression for 18 days. The mean fold increase curve ends at day 24 because this is 
the last time point at which at least two mice are still alive in each group. In comparison 
to the pcDNA+E+ treated mice, the mice treated with 100 μg pVpr plus electroporation 
had notable growth reduction over the course of the experiment especially from days 9  
through 16 post-treatment (Figure 10). There was no difference in the mean survival time 
since the mean survival time was 29.0 and 27.3 days for pVpr+ E+ and pcDNA3.1+ E+, 
respectively.  
Another experiment was conducted to further investigate the initial effect of three 
treatments with pVpr+ E+ in the context of the proper control groups. This experiment 
had an n=4 mice per group. Treatments were conducted on days 0, 2, and 4. The 
electroporation parameters were 1500 V/cm, 100 μs. The treatment groups were as 
follows: no treatment; 100 μg pVpr+E-; 100 μg pVpr+E+; 100 μg pcDNA3.1+E-; 100 μg 
pcDNA3.1+E+; and saline +E+ (electric pulses alone). The 100 μg pVpr+E+ group had 
the most tumor reduction compared to the other treatment groups. In fact, the B16 tumors 
grew so aggressively that by day 17 post-treatment, all the groups except for the 
untreated group and the 100 μg pVpr+E- group had enough mice still alive for 
meaningful statistical analysis. However, mice in the saline+E+ group were dead after 
day 17 post-treatment. Therefore, Day 17 was chosen as the end point for the mean fold 
increase analysis. The mean fold increase values were 2.17, 46.45, 4.46, and 10.44 for the 
group treated with 100 μg pVpr+E+, 100 μg pcDNA+E-, 100 μg pcDNA+E+, and 
saline+ E+, respectively (Figure 11). By day 24, one 100 μg pcDNA3.1+ E+ treated 
mouse experienced a complete tumor regression that lasted past 100 days post-treatment. 
 Figure 10. A Three Treatment Day Regimen Leads to Tumor Volume Reduction 
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Figure 11. Three Treatments with 100 μg pVpr Causes Tumor Growth Delay Three 
Weeks After Treatment 
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Optimal pVpr Treatment Regimen 
 
Optimal pVpr treatment is defined as the treatment regimen that not only yields 
tumor growth inhibition but long-term complete tumor regressions as well. Two protocols 
from the preliminary experiments yielded either short-term or long-term regressions. 
These regimens were further examined as optimal pVpr treatment regimens. 
 
Complete Regression of Established Subcutaneous B16 Tumors After Treatment with 
pVpr plus Electroporation  
To determine whether there was a therapeutic effect following the delivery of 
pVpr with electroporation, post-treatment tumor volume measurements were made to 
assess any attenuation of tumor growth as well as the induction of complete tumor 
regressions coupled with long-term survival. The average tumor volumes for each group 
ranged from 38 – 74 mm3. The electroporation parameters were 1500 V/cm, 100 μs. The 
tumors were treated with either 25 μg or 100 μg of pVpr on days 0 and 4 with or without 
electroporation. Figure 12 summarizes melanoma tumor growth in the different treatment 
groups during the initial 25 days of the experiment. Day 25 post-treatment was chosen as 
the end-point for the mean fold increase curve because this is the last time point at which 
a majority of the treated mice were still alive for accurate analysis. The absence of a 
mean fold tumor volume increase value at day 25 for a particular group indicates that all 
of the mice were dead by that time point.  
During the first week following treatment, tumor growth was inhibited to some 
extent in all the treatment groups when compared to the untreated control group 
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(i.e. Figures 12B, C and D versus A). Values for the mean fold increase in tumor volume, 
compared to day 0, were indicated for all the treatment groups through day 18 since at 
this point at least 50% of all of the mice in each of the treatment groups were still alive 
with the exception of 3 (21.4%) mice alive in the untreated group. At day 18 post-
treatment the mean fold tumor volume increases were significantly decreased (p<0.05) 
for the P+E+ 25 μg pVpr, P+E- 100 μg pVpr, and P+E+ 100 μg pVpr groups with values 
of 11.3, 21.2 and 7.6 , respectively, compared to the no treatment group (mean fold tumor 
volume increase of 45.4). The value for the P+E- 25 μg pVpr group was not significantly 
different to that of the no treatment group. Likewise, at day 18, the V+E- 100 μg 
pcDNA3.1 and V+E+ 100 μg pcDNA3.1 groups but not the saline plus electroporation 
group were significantly decreased compared to the no treatment group. For the groups 
with mean fold tumor volume increase values at day 25 , both the P+E+ 25 μg and P+E+ 
100 μg pVpr groups had significantly decreased values (i.e. 16.2 and 12.4, respectively) 
compared to the V+E+ 100 μg pcDNA3.1 group (i.e. 29) and the P+E- 100 μg pVpr 
group (i.e. 74.4). These results indicated an initial backbone vector plus electroporation 
effect, in terms of slowing of tumor growth. However, at day 25, the mean fold tumor 
volume increases for the pVpr plus electroporation treatment groups were significantly 
suppressed compared to the values measured in the pcDNA3.1 control plus 
electroporation group. 
While tumor reduction is an important evaluative criterion for assessing 
therapeutic potential, the critical parameter is the regression of existing tumors, i.e. a 
cure. Long-lasting tumor regressions were only observed in the groups that received the  
 
  
Figure 12. B16 Melanoma Tumor Growth Responses to pVpr Delivered with or without 
In vivo Electroporation. Mean Fold Increase in Tumor Volume (Compared to day 0) at 
Various Post-Treatment Time Points for the Different Treatment Groups: (A) No 
Treatment; (B) 25 μg pVpr with or without Electroporation; (C) 100 μg pVpr with or 
without Electroporation and (D) 100 μg pcDNA3.1 with or without Electroporation and 
Saline plus Electroporation. Reprinted, by permission, from Mol Ther 2006; 14:647-55
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pVpr +E+ (Table 1). The 100 μg pVpr+ E+ group had the highest percentage of mice 
with complete tumor regressions (42.9%) on day 14 post-treatment. In addition, on day 
14 post-treatment, mice that received 25 μg pVpr+ E+ or 100 μg pcDNA3.1+ E+ had 
complete tumor regressions in 14.3% and 7.1% of mice, respectively. It is important to 
note that the 100 μg pcDNA3.1 +E+ treated mouse that experienced tumor regression 
remained tumor free for only 4 days before recurrence of the tumor. At day 28 post-
treatment, 14.3% of mice treated with 25 μg pVpr +E+ and 21.4% of mice treated with 
100 μg pVpr +E+ had complete tumor regressions. It is important to indicate that none of 
the mice in the pcDNA3.1+ E+ treatment group underwent prolonged complete tumor 
regression nor did they survive long-term. This finding is presented in Figure 13. 
As indicated, the ultimately relevant end-point indicating the anti-tumor efficacy 
of the pVpr plus electroporation treatment would be the ability of this regimen to induce 
complete tumor regression coupled with long-term survival of the mice, i.e. a cure. 
Sustained tumor regression and survival for 100 days post-treatment is considered the 
benchmark for cure in mice in this model. Therefore, the survival rate and complete 
tumor regression status past 100 days were examined in this study. These data are 
presented in the Kaplan-Meier survival curve in Figure 13. Mice in the untreated group as 
well as groups receiving 25 μg or 100 μg pVpr without electroporation, pcDNA3.1 with 
or without electroporation, and saline plus electroporation all succumbed to tumor burden 
with none surviving to the day 100 benchmark. The mean survival time for untreated 
mice was 13.6 days. Mice in the untreated group had a significantly shorter survival time  
(p<0.05) when compared to groups that received either dose of pVpr+E+ or pVpr+E-, 
pcDNA+E+ or pcDNA+E-, & saline+E+. The mean survival time for mice treated 
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TABLE 1.  Percent of Mice with Complete Tumor Regressions 
Groups Day 14 Day 28 
No Treatment 0 N/A 
P+E- 25 ug pVpr 0 N/A 
P+E+ 25 ug pVpr 14.29% (2 out of 14) 14.29% (2 out of 14) 
P+E- 100 ug pVpr 0 N/A 
P+E+ 100 ug pVpr 42.86% (6 out of 14) 21.43% (3 out of 14) 
V+E- 100 ug pcDNA3.1 0 N/A 
V+E+ 100 ug pcDNA3.1 7.14% (1 out of 14)* 0 
Saline+E+ 0 N/A 
   
 
N/A indicates that all mice in this group are dead at this time point 
 
* indicates that this mouse only had tumor regression for 4 days before tumor recurred.  
 
Reprinted, by permission, from Mol Ther 2006; 14:647-55 
 
Figure 13. Kaplan-Meier Survival Curve of Mice in Different Treatment Groups up to 
100 Days Post- Treatment 
Reprinted, by permission, from Mol Ther 2006; 14:647-55 
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with 25 or 100 μg pVpr without electroporation, 100 μg pcDNA without & with 
electroporation, or saline plus electroporation (i.e. electric pulses alone) were 17.8, 19.4, 
19.3, 24.3 and 17.3 days, respectively. The mean survival times for the groups treated 
with 25 or 100 μg pVpr plus electroporation were 40.5 and 43.2 days, respectively. There 
was no statistical difference between the mean survival time for mice treated with 25 μg 
and 100 μg pVpr plus electroporation. 
Delivery of the plasmid with electroporation in the 25 μg or 100 μg pVpr 
treatment regimens resulted in complete tumor regression coupled with long-term 
survival at least for 100 days in 14.3% and 7.1% of the mice, respectively. Likewise, 
there was no statistically significant difference (p<0.05) between the regression/long-term 
survival rates in the 25 μg versus 100 μg pVpr plus electroporation treatment groups. 
 
Growth Inhibition and Regression after Multiple Treatments with pVpr plus 
Electroporation 
Experiments were conducted to examine the anti-tumor effect of electroporation- 
mediated delivery of pVpr administered on multiple treatment days. 100 μg of pVpr or 
pcDNA was administered with or without 1500 V/cm, 100 μs on treatment days 0, 2, and 
4. The initial mean tumor volumes ranged from 95 -122 mm3. The mean tumor volume 
was examined for the various groups for the first eight days after treatment. Day 8 is the 
last time point at which at least 50% of the mice were still alive in all the treatment 
groups. The mice that were treated with 100 μg pVpr plus electroporation had 
tremendous tumor reduction in comparison to the other treatment groups, especially 
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the mice treated with 100 μg pcDNA3.1 with electroporation (Figure 14). In addition to 
growth attenuation, complete tumor regression was evaluated as an indication of pVpr 
treatment efficacy. Twelve days after exposure to pVpr plus electroporation, 50% of the 
mice had complete tumor regressions. By day twenty-four post-treatment, 20% (2 out of 
10) of pcDNA3.1 plus electroporation treated mice had complete tumor regressions.  
Observations were made to determine whether electrically-mediated delivery of 
pVpr plus electroporation would prolong survival of tumor-bearing mice. We examined 
the survival of mice after the administration of various treatment regimens with the end 
point being 100 days after treatment (Figure 15). 50% of the pVpr treated mice that 
responded to treatment remained tumor-free for one-hundred days post-treatment. Also, 
there were 2 out of 10 mice treated with 100 μg pcDNA3.1 plus electroporation that were 
tumor-free for 100 days. The mean survival time for the mice treated with pVpr without 
electroporation, pcDNA without electroporation, saline with electroporation (electric 
pulses only), and untreated mice was 10.20, 8.90, 13.40, and 8.40 days, respectively. The 
mean survival time of mice treated with 100 μg pVpr plus electroporation was 61.80 
days. The 100 μg pVpr+ E+ treated mice lived significantly longer (p<0.05) than mice 
treated with 100 μg pVpr without electroporation, 100 μg pcDNA3.1 without 
electroporation, saline with electroporation, and untreated mice. The mean survival time 
for 100 μg pcDNA3.1 +E+ treated mice was 38.60 days. In terms of mean survival time, 
there was no statistical difference between mice treated with 100 μg pVpr+ E+ and 100 
μg pcDNA3.1+E+. 
 
  
Figure 14. Tumor Volume Reduction After Treatment with 100 μg pVpr on Days 0, 2, 
and 4 
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Figure 15. Kaplan-Meier Survival Curve After Treatment on Days 0, 2, and 4 
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Intratumoral Expression of Vpr In Vivo After Multiple Treatments  
Previous immunohistochemistry staining demonstrated Vpr expression at day 2 
after a single injection of 100 μg pVpr with electroporation but the protein expression 
diminished by day 4. The current experiment was conducted in order to determine 
whether multiple treatments of 100 μg pVpr with electroporation would lead to sustained 
Vpr expression for several days post-treatment. The multiple treatment regimen involved 
administering 100 μg pVpr plus 1500 V/cm, 100 μs on treatment days 0, 2, and 4. The 
tumors were sectioned to detect Vpr protein by immunohistochemistry. As early as day 2 
post-treatment (1 injection with pVpr plus electroporation on day 0), Vpr protein was 
detected (Figure 16A). Multiple treatments with 100 μg pVpr plus electroporation led to 
intense expression of Vpr at day 7 post-treatment (after 3 exposures to 100 μg pVpr plus 
electroporation) (Figure 16B). 
Summary of Specific Aim 1 
For the purpose of effectively treating subcutaneous B16 melanoma, certain 
treatment parameters had to be elucidated during the preliminary phase of 
experimentation. The parameters that had to be tested were the pVpr dosage, 
electroporation conditions, Vpr protein expression levels, and the schedule of treatment 
days. B16 melanoma lesions were treated with dosages ranging from 25 μg to 200 μg of 
pVpr plus electroporation on day 0 and day 4. Only the mice that received 100 μg pVpr 
plus electroporation had significant tumor reduction in comparison to the untreated mice. 
Therefore, the 100 μg pVpr dosage was chosen as the dosage to be further evaluated in 
subsequent growth inhibition studies in conjunction with electroporation. 
  
Figure 16. Vpr Expression on Day 2 and Day 7 Post-Treatment. (A) Tumor excised at 
day 2 post-treatment and stained with PE-conjugated Vpr antibody. (B) Tumor excised at 
day 7 post-treatment and stained with PE-conjugated Vpr antibody. 
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The next phase of the study examined four different electroporation parameters to 
determine which parameters would cause the highest Vpr protein expression after 
treatment with 100 μg pVpr +E+ on day 0 & day 4. The electroporation parameters that 
were investigated were 100 V/cm, 150 ms; 200 V/cm, 20 ms; 800 V/cm, 5 ms; and 1500 
V/cm, 100 μs. Also, it was found that Vpr protein was expressed two days following 
treatment and diminished by day 4 following treatment. The electroporation parameters 
of 1500 V/cm, 100 μs yielded the highest Vpr expression in comparison to the other 
electroporation parameters delivered with electroporation and pVpr alone. In addition to 
Vpr expression data, at the early time points (i.e. days 4 and 8), the 100 μg pVpr plus 
1500 V/cm, 100 μs treated tumors had the lowest tumor volumes compared to tumors 
treated with 100 μg pVpr without electroporation and all the other tumors treated with 
pVpr plus various electroporation parameters. 
The concentration of pVpr at 100 μg and the electroporation parameters of 1500 
V/cm, 100 μs pulses were sufficient to induce B16 tumor reduction but not durable 
complete responses. It was anticipated that in order to attain durable complete tumor 
regression, the schedule of treatment days would have to be revised. The initial treatment 
regimen involved treatments on days 0 & 4 but new avenues would have to be explored 
such as daily treatment days or alternating treatment days on the quest to attain complete 
regressions. Treatments on days 0, 4, 7 and 11 led to mice that lived significantly (p< 
0.05) longer than untreated mice following treatment with P+E+ 50 μg pVpr or P+E+ 
100 μg pVpr. The four day treatment regimen suggested that closer intervals of treatment 
may be necessary to obtain more reduction in tumor volume.  
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Closer intervals of treatment were examined with the treatment regimen of 
consecutive treatment days (i.e. day 0 and 1) or alternating treatment days (i.e. 0 and 2). 
Initially, the consecutive treatment regimen of pVpr +E+ caused more reduction in tumor 
volume than the alternating treatment regimen. By the second week after treatment with 
pVpr +E+, the alternating treatment appeared more effective in reducing tumor volume.  
Since the consecutive treatment (i.e. day 0 and day 1) regimen yielded a reduction 
of tumor growth at the early time points, another experiment was conducted to determine 
whether daily treatments of pVpr +E+ (i.e. day 0 –day 7) would induce tumor reduction 
and complete regression. Daily treatments with 100 μg pVpr + E+ once daily or 100 μg 
pVpr + E+ twice daily led to 80% of mice with durable complete tumor regressions. One 
mouse had durable complete regression following every other day treatment with 100 μg 
pVpr + E+. Also, 100 % of the mice had durable complete regressions after treatment 
with 100 μg pcDNA3.1. Since 80- 100 % of mice treated daily with pVpr + E+ or 
pcDNA3.1 +E+ had complete regressions, a difference between pVpr and non-coding 
vector could not be established. Therefore, in order to possibly differentiate between the 
efficacy of pVpr and pcDNA3.1, a revised treatment regimen was devised. The revised 
treatment regimen stems from evidence that alternating treatment days of pVpr +E+ led 
to tumor reduction with the only modification being an additional day incorporated into 
the regimen (i.e. day 0, 2, and 4). 
Once the optimal electroporation parameters were found, several main 
experiments were conducted to determine the efficacy of tumor reduction and/or 
regression as a consequence of using the optimal pVpr dosage as well as the optimal 
electroporation parameters. The set of experiments to demonstrate B16 tumor regression 
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involved treating mice with 25 μg or 100 μg pVpr plus electroporation. The experiments 
were repeated twice for a total n of 14 for the pVpr +E+ and the pcDNA3.1 +E+ group. 
By day 14 post-treatment, 42.86% of the mice had complete tumor regressions following 
treatment with 100 μg pVpr plus electroporation. Also, by day 14, 14.29% of the mice 
had complete tumor regressions following treatment with 25 μg pVpr plus 
electroporation. Due to residual tumor cells, tumors recurred in the mice that were treated 
with 100 μg pVpr plus electroporation which left 7.14% of these mice with complete 
regression past 100 days post-treatment. Whereas, 14.29% of the mice treated with 25 μg 
pVpr+E+ maintained regression past 100 days post-treatment.  
Another set of experiments were devised from the concepts developed in the 
preliminary experiments regarding the alternating treatment regimen (i.e. day 0 and day 2 
treatment) for enhanced tumor reduction with tumor regression. The modification in this 
set of experiments was that treatment was administered on day 0, 2, and 4. The 
experiments were repeated twice for a total n of 10. Mice were treated with 100 μg pVpr 
or 100 μg pcDNA3.1 with electroporation. After 100 days post-treatment, 50 % of pVpr 
+E+ treated mice and 20% of pcDNA3.1 +E+ treated mice had complete tumor 
regressions. Therefore, 100 μg pVpr with 1500 V/cm, 100 μs administered on days 0, 2, 
and 4 yielded the highest percentage of durable complete regressions.  
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Specific Aim 2 
To Elucidate a Mechanism Regarding the Ability of Vpr to Inhibit Tumor Growth In Vivo 
 
Apoptosis is the Mechanism of Tumor Reduction 
Previous in vitro studies have demonstrated that Vpr protein induces apoptosis in 
a variety of cancer cell lines (54,83). However, there has not been a definitive in vivo 
study that shows that Vpr protein induces intratumoral apoptosis and has a role in B16 
tumor reduction. The tumors used in this portion of the study were treated according to 
the two protocols for the optimal pVpr +E+ treatment regimen. The first protocol 
involved treating tumors with the high dose group, 100 μg pVpr +E+ on days 0 and 4. 
The second protocol involved treating tumors with 100 μg pVpr +E+ on days 0, 2, and 4.  
It was important to determine the in vivo Vpr expression efficiency and any Vpr 
induced apoptosis after intratumoral injection of pVpr into established subcutaneous B16 
tumors with in vivo electroporation. Initially, to address this issue, melanoma tumors 
were excised 48 hours after a single intratumoral treatment with 100 µg of pVpr 
delivered with electroporation. After appropriate sectioning and tissue fixation, tumor 
sections were stained with a rabbit polyclonal anti-Vpr antibody and a TUNEL reaction 
mixture for measurement of protein expression and apoptosis, respectively (Figure 17). 
After examination of the sections by fluorescent microscopy under dual filters the areas 
of fluorescence, indicative of expression of Vpr and apoptosis, were assessed. Figure 17A 
and 17B show tumor sections from pVpr +E+ treatment and pcDNA3.1 +E+ treatment 
which were stained with Hoechst reagent, which is a positive control which stains nuclei. 
Figures 17C and 17D indicate PE conjugated anti-Vpr antibody staining for the pVpr plus 
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electroporation and pcDNA3.1 control plus electroporation groups, respectively. 
Although some background staining is present in the pcDNA3.1 section, staining in the 
pVpr section is considerably more extensive and intense indicating expression of Vpr. 
Figures 17E and 17F show overlays of the tumor sections indicating Vpr and Hoechst 
staining of pVpr plus electroporation and pcDNA3.1 plus electroporation treatment 
groups, respectively. The panels in Figures 17G and 17H indicate Hoechst staining for 
consecutive sections from the pVpr and pcDNA3.1 treated tumors and serves as the 
positive control for nuclei in the TUNEL staining. Finally, Figures 17I and 17J show 
TUNEL staining (specifically nuclear staining) of sections from tumors treated with pVpr 
plus electroporation and pcDNA3.1 plus electroporation, respectively. This result 
demonstrated specific TUNEL staining (fluorescein), indicative of apoptosis, only in the 
pVpr plus electroporation treatment group. In summary, the results demonstrate specific 
Vpr expression and apoptosis induced by the Vpr DNA construct when delivered 
intratumorally, with electroporation, into these aggressive and established subcutaneous 
B16.F10 tumors. Overall, the data demonstrate the ability of a plasmid expressing Vpr, 
when delivered electroporatively to B16.F10 tumors, to effectively result in long-term 
survival of treated mice coupled with complete tumor regression. 
Additional studies were conducted to evaluate whether apoptosis is the 
mechanism by which Vpr inhibits tumor growth and causes tumor regression in vivo. 
Tumors that were exposed to pVpr plus electroporation demonstrated apoptosis as early 
as two days post-treatment and continued to undergo apoptosis for a number of days 
following treatment (Figure 18). Hoechst was used as a positive control for nuclei in the 
PE-conjugated anti-Vpr antibody staining of all the tumor sections. Figure 18 (A-C)  
  
 
 
Figure 17. Day 2 In Vivo Expression of Vpr and Induction of Apoptosis After pVpr 
Treatment with Electroporation 
Reprinted, by permission, from Mol Ther 2006; 14:647-55 
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shows tumor sections from pVpr +E+, pcDNA3.1 +E+, and saline +E+ groups, 
respectively. These results show the overlays of the tumor sections indicating expression 
of Vpr and Hoechst staining. Figure 18 (D-F) indicates Hoechst staining for sections from 
pVpr +E+, pcDNA3.1 +E+, and saline +E+ treated tumors, respectively. Hoechst serves 
as the positive control for nuclei in the TUNEL staining. Figures 18 (G-I) show TUNEL 
staining of sections from tumors treated with pVpr +E+, pcDNA3.1 +E+, and saline +E+, 
respectively. This data showed specific TUNEL staining (fluorescein), which signified 
apoptosis, only in the pVpr +E+ treated tumors. Irrespective of multiple treatments, 
negligible apoptosis levels, slightly above background levels, were observed in tumors 
treated with electric pulses only or 100 μg pcDNA3.1 with electroporation. After three 
treatments, 100 μg pVpr alone induced apoptosis but not as efficiently as electroporation-
mediated delivery of 100 μg pVpr (data not shown). 
Summary of Specific Aim 2 
The purpose of Specific Aim 2 was to elucidate a mechanism regarding the ability 
of Vpr to inhibit tumor growth and cause regression in vivo. Previous in vitro studies 
demonstrated Vpr-induced apoptosis. The current study demonstrated for the first time 
that Vpr protein caused apoptosis in established B16 tumors. Vpr protein induced 
apoptosis as early as two days after the intratumoral delivery of pVpr with 
electroporation. Also, sustained apoptosis corresponded to sustained Vpr expression for 
up to seven days following intratumoral treatment with 100 μg pVpr +E+ on days 0, 2, 
and 4. Data suggest that intratumoral apoptosis is the mechanism by which Vpr protein 
causes B16 tumor regression. 
 Figure 18. Day 7 Immunohistochemical Staining and Apoptosis Staining of Tumor 
Treated with Three Treatments of pVpr+E+ 
 
 73
 74
Specific Aim 3 
To Investigate whether pVpr Induces an Immune Response, which would allow the 
Treated Mice to be Resistant to Tumor Challenge 
 
Cured Mice Resist B16.F10 Challenge  
During the course of conducting research pertaining to electrically-mediated 
delivery of pVpr to established melanoma, several mice had durable complete regression, 
cured, of cancer. To examine whether these mice were able to resist future exposure to 
the parental cancer cells, B16.F10 melanoma cells were injected on the right flank (i.e. 
the flank opposite to the one that was originally treated). The initial challenge 
experiments involved injecting 1x106 of B16.F10 cells, the original concentration, on the 
opposite flank of cured mice. The latter challenge experiments involved injecting 5x105 
B16.F10 cells on the opposite flank of cured mice. Cured mice were challenged after 
remaining tumor-free for ~ 100 days post-treatment. By using 1x106 or 5x105 B16.F10 
cells in some of the challenge experiments, it was determined that the amount of parental 
cells does not influence whether cured mice are able to resist tumor challenge. It was  
customary to inject naïve C57Bl/6 mice with the same batch of B16.F10 cells that were 
used in the challenge experiments as a control for their viability in the cured mice. All 
cured mice that resisted tumor challenge were also monitored for continued complete 
regression at the original treatment site. 
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Cured Mice Resist Tumor Challenge Following Treatment with pVpr plus 
Electroporation on Days 0 and 4 
Both the low and high dosage pVpr treatment regimen delivered with 
electroporation yielded cured mice that were able to resist tumor challenge. Following 
treatment with 25 μg of pVpr +E + on days 0 and 4 post-treatment, two out of fourteen 
mice were cured. The two 25 μg pVpr +E+ treated mice were challenged with 1x106 
B16.F10 cells on the opposite flank (right flank). By day 10 post-challenge, a tumor 
appeared at the challenge site on one of the 25 μg pVpr +E+ treated mice, whereas the 
other 25 μg pVpr +E+ treated mouse resisted tumor challenge until the end of the time 
course at 52 days post-challenge. Following treatment with 100 μg pVpr +E+ on day 0 
and day 4, one out of 14 mice were cured. The mouse previously treated with 100 μg 
pVpr +E+ was challenged with 1x106 B16.F10 cells on the opposite flank. The 100 μg 
pVpr +E+ treated mouse resisted tumor challenge for 41 days post-challenge before a 
tumor appeared at the challenge site.  
An additional experiment with pVpr +E+ administered on days 0 & 4 yielded 
cured mice which were later challenged with B16.F10 cells. One mouse was cured 
following treatment with 100 μg pVpr +E+ on days 0 & 4 post-treatment. The 100 μg 
pVpr +E+ treated mouse resisted tumor challenge for 54 days post-challenge. Two mice 
were cured following treatment with 100 μg pcDNA3.1+ E+. By day 31 post-treatment, 
only one of the100 μg pcDNA3.1+ E+ treated mice resisted tumor challenge until day 54 
post-challenge. 
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Cured Mice Resist Tumor Challenge Following Daily Administration of pVpr plus 
Electroporation 
Mice that were previously cured after receiving various daily treatments of 100 
μg pVpr with or without electroporation were challenged with 1x106 B16.F10 cells on the 
right flank. Following treatment with 100 μg pVpr +E+ twice daily, four out of five mice 
were cured. Of the cured mice treated with 100 μg pVpr +E+ twice daily, two mice 
resisted challenge for the first eleven days post-challenge. By day 16 post-challenge, all 
the twice daily pVpr + E+ treated mice succumbed to tumor occurrence at the challenge 
site. Four out of five mice treated with 100 μg pVpr +E+ once daily were cured. Only 
three of the once daily treated mice were challenged with 1x106 B16.F10 cells because 
the other cured mouse in this group was excluded (i.e. euthanized) from the challenge 
experiment due to a persistent skin irritation. All three mice treated with once daily pVpr 
+E+ were able to resist tumor challenge until the end of the time course at 39 days post-
challenge. One mouse was cured following treatment with 100 μg pVpr + E+ 
administered on days 0, 2, 4, & 6. The mouse previously cured with pVpr +E+ on days 0, 
2, 4, & 6 resisted tumor challenge for 39 days post-challenge which was the end point for 
this experiment.  
 
Cured Mice Resist Tumor Challenge Following Treatment with pVpr plus 
Electroporation on Days 0, 2, and 4 
In one of the preliminary experiments, one out of four mice were cured after 
receiving day 0, 2, & 4 treatments of 100 μg pcDNA3.1 +E+ and challenged with 5x105 
B16.F10 cells on the right flank. However, the pcDNA3.1 +E + treated mouse did not 
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resist tumor challenge. Mice that were previously cured after receiving day 0, 2, & 4 
treatments of 100 μg pVpr +E+ were challenged with 5x105 B16.F10 cells on the right 
flank. Day 50 post-challenge is the end point for the experiment. Following treatment 
with 100 μg of pVpr +E + on days 0, 2, and 4 post-treatment, five out of ten mice were 
cured. At day 11 post-challenge, four mice resisted tumor challenge. On days 39 to 50 
post-challenge, three mice resisted tumor challenge. Following treatment with 100 μg of 
pcDNA3.1 +E + on days 0, 2, and 4 post-treatment, two mice were cured. At the day 11 
post-challenge time point, one of pcDNA3.1+ E+ cured mice already had a tumor that 
had developed for over a week. The other pcDNA3.1+ E+ cured mouse resisted tumor 
challenge for 50 days post-challenge.  
Summary of Specific Aim 3 
The purpose of Specific Aim 3 was to determine whether pVpr induces an 
immune response, which would allow the treated mice to be resistant to tumor challenge. 
Cured mice were challenged with parental B16.F10 cells after remaining tumor-free for ~ 
100 days post-treatment. After mice were treated with 25 μg pVpr +E+ or 100 μg pVpr 
+E+ on days 0 and 4, 2 out of 14 mice or 1 out of 14 mice resisted tumor challenge, 
respectively, for at least 41 days. Three out of five mice and one out of five mice resisted 
tumor challenge following pVpr +E+ treatment delivered once daily and every other day, 
respectively. Following treatment with pVpr +E+ on days 0, 2, and 4, three out of 10 
mice resisted tumor challenge. Following treatment with pcDNA3.1+E+ on days 0, 2, 
and 4, one out of 10 mice resisted tumor challenge. 
It is important to point out that naïve mice usually develop tumors within one 
week of tumor challenge and succumb to tumor burden between days 15 and 20. Also, all 
 78
of the challenged mice survived at least 39 days after challenge. In some instances mice 
survived 52 days after challenge. Therefore, the cured mice that were able to resist B16 
challenge lived tumor-free for over a month after exposure to the parental B16.F10 cells. 
This finding suggests that the pVpr plus electroporation treatment most likely elicited an 
immune response which is involved in protecting challenged mice from tumor 
development at a time point where there would be significant tumor burden in naïve 
animals. 
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Discussion 
The B16.F10 murine melanoma model was selected for this study because this 
tumor cell line has been extensively characterized and is a very good model for many 
human malignancies due to its highly invasive and metastatic nature. In particular, 
B16.F10 melanoma is a good model for human melanoma because it is poorly 
immunogenic due to the lack of MHC I expression and its tumor associated antigens are 
recognized as self antigens (29,30). It is difficult to attain complete tumor regressions, 
coupled with long-term survival, through therapeutic interventions in established 
subcutaneous B16 tumors. The main reason that untreated B16.F10 tumors grow so 
aggressively is that mice are incapable of mounting a proper immune response against 
this poorly immunogenic tumor.  
B16.F10 melanoma is characteristically difficult to treat or cure once visible 
tumors have developed. Most researchers are only able to obtain B16 tumor growth delay 
for a period of time before the tumor burden necessitates euthanization of the animal. 
Typically in this model any therapeutic intervention resulting in only tumor growth delay 
is considered to be significant. Usually, untreated B16 tumor-bearing mice die by day 21-
25 after inoculation of cells. In addition, it is significant that in the current study the 
treatment regimen was delivered to established tumors rather than administered either 
concomitantly with initial tumor cells or before tumors had visibly formed. The qualities 
of B16 melanoma contribute to its attractiveness as a model for human tumors.  
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Many investigations have determined that the HIV-1 accessory protein Vpr 
induces apoptosis in a large variety of tumor cells in vitro (34,35,102). While many 
studies examined the anti-cancer activity of Vpr in vitro concurrent with a mechanism of 
cell killing, there was little research to address the anti-cancer effects of Vpr in vivo. 
There were a few exceptions in which anti-cancer activity of Vpr was examined in mouse 
models.  
Eventually, the anti-cancer activity of Vpr was examined in a solid tumor model. 
Lentiviral delivery of Vpr to AT-84 oral cancer in a mouse model demonstrated the 
capability of Vpr to cause tumor regression (103). In the AT-84 study, low infectivity 
rates of lentiviral vector carrying Vpr led to 10% of transfected cells that were apoptotic 
in vitro. However, in the AT-84 study, tumors that were exposed to Vpr were shown to 
have regions of dead cells but there was no distinction as to whether the dead cells arose 
because of necrosis or apoptosis.  
There are some safety issues concerning the use of lentiviral vectors in clinical 
settings. One negative aspect of using lentiviral vectors is that there could be potential 
adverse reactions if multiple lentiviral treatments were administered in an effort to 
optimize the treatment regimen. Another negative aspect is that lentiviral delivery could 
cause insertional mutagenesis in the host genome (104). The AT-84 study showed the 
feasibility of using the Vpr gene product to slow tumor growth and cause tumor 
regression in a mouse model. But the study did not provide a gene delivery system that 
could be safely translated into future clinical utility. Even though vpr could be inserted 
into another viral vector such as an adenoviral vector, in the case of multiple treatment 
administrations, it would be difficult to circumvent immune reactions due to multiple 
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exposures to the viral vector. An effective non-viral delivery method such as 
electroporation would offer a way avoid immune responses to viral vectors.  
Specific attention has been focused on the impact that Vpr has on B16.F10 cells. 
There was a study that investigated the role of Vpr on B16.F10 tumor cell proliferation in 
an animal model but the study was performed by transfecting the B16 cells with Vpr 
plasmid prior to injecting the cells into mice. The previous investigation reported that 
B16.F10 melanoma cells, when transfected with a plasmid expressing Vpr, were 
significantly less efficient in inducing tumor colonies in the lungs of C57BL/6 mice 
following intravenous injection (105). The study reported here is the first to investigate 
the impact of Vpr on established subcutaneous B16.F10 melanoma.  
The hypothesis of this study: Intratumoral delivery of a Vpr expression plasmid 
administered with in vivo electroporation will lead to growth inhibition and regression of 
established B16.F10 melanoma in syngeneic C57BL/6 mice.  
The successful use of electroporation to transfer plasmid to cells in vitro and the 
fact that electric fields can be safely and efficiently administered in vivo to deliver small 
molecules offered a basis for the delivery of plasmid via in vivo electroporation 
(106,107). Several studies have demonstrated that electrically mediated delivery of 
plasmids which encode and express therapeutic molecules can be directed efficiently to 
tumors. Examples involving experimental melanoma treatment indicated that delivery of 
plasmids encoding GM-CSF and IL-2, IL-12 , tumor antigens and IFN-α elicit an anti-
tumor effect (95,98-101,108,109).  
In terms of electrogenetherapy, complete tumor regressions of established B16 
tumors have been attained mostly with the use of plasmids encoding for cytokines. 
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Furthermore, the most efficient transfection method to induce complete B16 regressions 
has been in vivo electroporation. Therefore, in vivo electroporation was utilized as a 
delivery method in order to maximize the potential for a therapeutic effect of Vpr when 
administered as an expression plasmid.  
In the study reported here, preliminary data demonstrated that after the 
electrically-mediated delivery of pVpr, intratumoral Vpr expression lasted for two days 
after a single administration of treatment. It was later discovered that intratumoral Vpr 
expression caused intratumoral apoptosis at two days post-treatment. Therefore, various 
treatment regimens were explored in order to obtain a sustained level of Vpr expression 
while at the same time improving the ability of Vpr to reduce B16 tumor volume and/or 
induce complete regression. For these reasons treatment regimens such as daily 
treatments (i.e. day 0- day 7) and alternating treatments (i.e. day 0, 2, and 4) were 
examined. With the daily treatment regimen there was no way to differentiate between 
Vpr induced or non-coding vector induced complete tumor regressions considering that 
80 – 100% of treated mice had complete regressions within the same timeframe. 
Therefore, the alternating treatment regimen (i.e. day 0, 2, and 4) resulted in 50% of the 
mice having complete regressions after pVpr +E+ treatment and 20% of the mice having 
complete regressions after pcDNA +E+ treatment. At least with alternating treatments, a 
distinction could be made between the time points at which complete regression occurred 
for the pVpr +E+ treated mice and the pcDNA + E+ treated mice. Mice treated with pVpr 
+E+ on days 0, 2, & 4 had complete tumor regressions by week two after treatment. 
Whereas, mice treated with pcDNA +E+ on days 0, 2, & 4 had complete tumor 
regressions by 3- 4 weeks after treatment. Thereby, a distinct mechanism of tumor 
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regression could be proposed for the pVpr treatment and the non-coding treatment 
administered on alternating treatment days. Upon further investigation it was found that 
the tumors treated with multiple days of pVpr+ E+ underwent apoptosis, whereas the 
tumors treated with multiple days of pcDNA3.1 +E+ did not experience apoptosis. 
In this study, Vpr has shown great potential as an anti-tumor agent in terms of 
attenuation of B16 tumor growth and complete tumor regressions. During the first twelve 
days following treatment, mice that received day 0, 2, & 4 treatments of 100 μg pVpr 
with electroporation had substantial reductions in tumor volume in comparison to the 
other treatment groups. By day 12 post-treatment, the tumor reductions translated into 
complete tumor regressions in 50% of the pVpr plus electroporation treated mice. The 
enhanced expression of Vpr correlates with greater apoptosis within the tumor which 
would allow for greater reduction in tumor volume.  
The Vpr protein is a fast-acting protein which is produced within 48 hours 
following a single electrically-mediated pVpr injection. Tumors that were initially treated 
with pVpr plus electroporation not only demonstrated apoptosis as early as 48 hours post-
treatment but continued to undergo apoptosis for a number of days following three 
treatments. After multiple exposures to pVpr plus electroporation, Vpr –induced 
apoptosis could possibly enhance the ability of the immune cells to recognize the B16 
tumor antigens derived from apoptotic B16 tumors. It is a possibility that after treatment 
with pVpr+ E+, there could be improved availability of B16 antigens which might 
increase the likelihood that this ordinarily poorly immunogenic tumor would be 
recognized by antigen presenting cells which in turn would be engaged by cytotoxic T 
cells to destroy the tumor (110,111). 
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It is commendable that Vpr had the capability to induce tumor regressions through 
an apoptotic-mediated mechanism in the B16.F10 melanoma model which is known for 
its highly aggressive nature and tendency to recur even after complete regressions occur. 
Therefore, due to its apoptosis-inducing properties, it is anticipated that the pVpr +E+ 
treatment would be effective in eradicating less aggressive tumors which could result in 
higher percentages of complete regressions. 
It is important to note that gene delivery via electroporation enhanced the Vpr 
gene expression as evidenced by the tumors treated with pVpr +E+ producing a 
sufficiently high level of Vpr protein to induce apoptosis. At low levels of expression, 
Vpr protein will not cause apoptosis, thereby Vpr protein will exhibit an anti-apoptotic 
effect (79,80). There was a possible anti-apoptotic effect exhibited when tumors treated 
with pVpr without electroporation expressed Vpr protein but not at sufficiently high 
levels to cause apoptosis (data not shown). Even when pVpr was administered without 
electroporation on three treatment days, pVpr alone did not cause substantial apoptosis. 
Whereas, after a single treatment with pVpr +E+, apoptosis was induced. The current 
study definitively showed that the delivery of pVpr via electroporation allowed for a high 
level of Vpr protein expression. The high level of Vpr protein expression led to B16 
tumor regression which was mediated through apoptosis.  
The pVpr + E+ treatment regimen not only eradicates the primary B16 melanoma 
but can offer protection against future B16 melanoma development. Once mice had 
complete tumor regression for approximately 100 days after treatment they were 
considered cured of B16 melanoma. The cured mice were challenged with B16.F10 cells 
to determine whether they developed an immune response against the tumor cells. After 
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mice were treated with 25 μg pVpr +E+ or 100 μg pVpr +E+ on days 0 and 4, 2 out of 14 
mice or 1 out of 14 mice were cured and resisted tumor challenge for at least 41 days. 
Following the daily treatment regimen there were some mice that were able to resist 
tumor challenge in the groups that were previously cured with once daily 100 μg pVpr 
+E+ and every other day with 100 μg pVpr +E+. Following treatment with pVpr +E+ on 
days 0, 2, and 4, three out of 10 mice were cured and resisted tumor challenge. Following 
treatment with pcDNA3.1+E+, two out of 10 mice were cured but only one of these mice 
resisted tumor challenge. Previous studies have indicated that under the right conditions a 
high percentage of mice experience long-term protection against parental tumor 
following treatment with either an electrically-mediated non-coding vector or CpG-ODN 
(112,113). However, in the current study, long-term protection against B16 melanoma 
occurred more often in mice cured with one of the pVpr+ E+ treatment regimens as 
opposed to the pcDNA3.1 +E+ treatment regimen. 
In some instances, there were durable complete regressions observed after 
treatment with either pVpr or pcDNA3.1 plus electroporation. The data from the daily 
pVpr or pcDNA3.1 plus electroporation treated tumors indicate, even though both 
treatment regimens resulted in complete tumor regression, the Vpr exposed tumors 
responded by 11-12 days post-treatment in the once daily group, the group that received 
pVpr+E+ on days 0, 2, 4, and 6, and group that received pVpr+E+ on day 0, 2, & 4. 
Whereas, the pcDNA+E+ treated tumors had complete tumor regression by day 18 -24 
days post-treatment. In addition, 50% of the pVpr+ E+ treated mice had regressions from 
day 12 post-treatment until day 100 post-treatment with pVpr +E+ on days 0, 2, and 4. 
The non-coding vector effect (i.e. pcDNA3.1+ E+) took approximately three weeks to 
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cause regression in a minimal number of mice with the remainder of these mice dying by 
~ day 30 post-treatment. Even though 2 out of 10 pcDNA+E+ treated mice remained 
tumor-free for 100 days, a greater percentage of mice exposed to pVpr +E+ remained 
tumor-free for 100 days. The difference in timing of regression and the fact that 
pcDNA+E+ treatment induces only minimal intratumoral apoptosis, suggests that Vpr-
induced tumor regression and pcDNA-induced tumor regression occurs based on two 
different mechanisms. A possible mechanism for pcDNA induced regression is 
immunostimulatory CpG motifs in the vector backbone. 
By using electrically-mediated delivery of plasmid encoding for Vpr or a non-
coding plasmid, this research demonstrates two different pathways to induce complete 
tumor regression of a poorly immunogenic, aggressive tumor. The first pathway involves 
inducing apoptosis via intratumoral Vpr protein expression. The second pathway involves 
evoking an immune response against tumor antigens. Interestingly, both pathways result 
in lifelong immunity against B16 melanoma in this mouse model.  
Previous research involving CpG-ODNs (oligodeoxynucleotides which include 
CpG motifs) demonstrated that basic peritumoral injections of CpG-ODNs alone had the 
capability of eradicating established tumors and inducing long-term immunity against the 
parental tumor (112,114). It is feasible to speculate that electroporation more efficiently 
delivers the non-coding plasmid containing CpG motifs directly into the tumor, thereby 
possibly allowing eradication of the tumor in a similar manner as the CpG-ODNs. An 
earlier electroporation study indicated that delivering non-coding vector with 
electroporation caused complete tumor regression and long-term immunity in an 
established B16 melanoma (113). An additional study suggests that a possible source of 
 87
tumor regression in non-coding vector treated mice may be immune cell infiltration due 
to the CpG motif in the vector (115). Also, perhaps, the more efficient delivery of the 
non-coding plasmid induced complete tumor regression in the current study after 2-7 
injections of plasmid with electroporation, whereas, the delivery of CpG-ODNs required 
15 basic injections to obtain complete tumor regression in a solid tumor (112). Even 
though established neuroblastoma is a difficult tumor to treat, the use of CpG-ODNs 
offered a way to cure tumor-bearing mice from this solid tumor (112,116). Therefore, the 
CpG motifs could contribute to the cure of the B16 solid tumor in the current study. 
The mechanism by which CpG-ODNs induce tumor regression involves NK cells, 
dendritic cells, macrophages, and T cells. There have been recent investigations 
concerning the use of CpG-ODNs in the treatment of melanoma in a pre-clinical 
melanoma model (117,118). Delivery of non-coding plasmid with electroporation is less 
labor intensive than CpG-ODNs synthesis and may have future utility in treatment of 
cancer via non-specific as well as tumor-specific immunity. 
This study initially demonstrated the feasibility of using a plasmid encoding for 
Vpr delivered by in vivo electroporation to successfully treat established B16 tumors, 
which resulted in growth inhibition and ultimately regression. This is the first 
comprehensive study demonstrating the ability of Vpr, when delivered as a plasmid via in 
vivo electroporation, to induce complete tumor regressions in a solid tumor. Even though 
a lentiviral vector carrying Vpr demonstrated tumor regression in AT-84 tumors, there 
are safety concerns regarding the use of lentiviral vectors in the clinical setting. The 
current study is the first one to deliver pVpr by in vivo electroporation which allows for 
multiple treatments without potential immune reactions. As the study continued, it 
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showed that the tumor inhibition and regression corresponded to the intratumoral Vpr-
induced apoptosis. Previous research had only shown Vpr protein expression and its 
resultant apoptosis in vitro. The current study offers one of the first evidences which 
demonstrate in vivo apoptosis as a result of Vpr protein expression. Also, this study was 
the first to demonstrate an optimized treatment regimen by incorporating closer intervals 
between treatments in order to attain higher percentages of B16 tumor regressions. In the 
future, after additional pre-clinical studies, electrically-mediated pVpr may be efficacious 
against human cancer.  
The ultimate therapeutic endpoint was complete tumor regression and long- term 
survival rather than simply attenuation of tumor growth which has been the benchmark of 
most other studies. Therefore, the percentages of the complete tumor regression coupled 
with long-term survival attained in this study with pVpr plus electroporation treatment 
are biologically significant and warrant further mechanistic studies as well as the 
assessment of methods to maximize the anti-tumor effect through the use of different 
plasmid doses and Vpr treatment regimens. In addition, once the anti-tumor effect can be 
further maximized for the pVpr+ E+ treated mice, potential immune mechanisms, such as 
potential presentation of specific melanoma tumor antigens released by the apoptotic 
process, could be further investigated. Overall, the data presented underscore the 
therapeutic anti-tumor activity of both Vpr and the electroporation delivery method and 
suggests a potential clinical utility for this treatment modality against melanomas as well 
as possibly other tumor types. In sum, the data suggest that gene delivery using Vpr 
provides a way to harness the cell killing potential of Vpr in HIV infected hosts and 
utilize it against malignant tumors such as melanomas.
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Future Directions 
Completion of this study established an understanding of the anti-tumor effects of 
intratumoral delivery of a Vpr expression plasmid mediated through in vivo 
electroporation. This study also demonstrated apoptosis as a mechanism of action for Vpr 
protein induced tumor regression in the B16 tumor model. This study serves as a 
foundation for future studies to investigate the further implications of the capability of 
Vpr protein to cause growth inhibition and regression in solid tumors. 
Further experiments should be proposed to extend our understanding of how Vpr 
induces tumor regression. For example, experiments should be conducted to determine if 
and to what extent intratumoral immune cells such as T cells, NK cells, dendritic cells, 
and macrophages contribute to tumor regression in B16 tumors that have been treated 
with pVpr +E+. Another approach to determine the importance of T-cell mediated 
immunity in Vpr induced tumor reduction would be to use a nude mouse model. 
It would be interesting to further evaluate whether there are anti-proliferative 
effects after the delivery of pVpr plus electroporation in other tumor models especially 
human melanoma. In this case, human malignant melanoma cells such as A375 cells 
would be injected into nude mice in order to establish a tumor. Subsequently, the A375 
tumor would be treated with pVpr+E+. The nude mouse model would provide a way to 
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determine the capability of Vpr protein to have anti-tumor activity in the context of the 
innate immune system. 
It would be interesting to examine other apoptosis-inducing HIV-1 accessory 
proteins in the context of the B16 established tumor. Since B16.F10 is highly aggressive, 
it would be a good tumor model to test any anti-tumor activity of other HIV-1 accessory 
proteins. Experiments could be conducted to determine whether electrically-mediated 
delivery of other accessory HIV-1 genes would have the capability to inhibit B16 growth 
or cause B16 tumor regression. Thus far, Nef has been shown to cause growth inhibition 
in a tumor model (119). It may even be efficacious to combine Vpr with one of the other 
HIV-1 accessory proteins to test for synergistic anti-tumor capabilities.  
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